The effects of hypoxis hemerocallidea on blood glucose levels in rats with Type 2 diabetes by Elshawesh, Mohamed Abdallah
  
 
THE EFFECTS OF HYPOXIS 
HEMEROCALLIDEA ON BLOOD GLUCOSE 
LEVELS IN RATS WITH TYPE 2 DIABETES 
 
 
 
 
By 
 
MOHAMED ABDALLAH ELSHAWESH (BSc) 
 
 
 
A thesis submitted in partial fulfilment of the requirements for the degree of 
Magister Scientiae, in the Department of Medical Bioscience, University of the 
Western Cape. 
 
 
 
 
Supervisor: Prof. Daneel Dietrich. 
(MBS, University of the Western Cape). 
 
Co supervisor: Dr .Venant Tchokonte-Nana. 
                                        (FMHS, Stellenbosch University). 
 
November, 2015 
 
 
 
 
  
I 
 
KEYWORDS 
 
Diabetes 
Type 2 diabetes mellitus 
Hypoxis hemerocallidea 
High-fat diet 
Streptozotocin 
Intraperitoneal Glucose Tolerance 
Free fatty acid 
Pancreatic β-cells 
Insulin secretion 
Insulin resistance  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
II 
 
ABSTRACT 
 
About 180 million people have been estimated to suffer from type 2 diabetes 
(T2DM) in 2006 and the annual death rate due to this disease was 3 million by 
that time. More than 400 medicinal plants used for the treatment of diabetes 
mellitus have been recorded, but only a small number of these plants have 
received scientific and medical evaluation to assess their efficacy. The most 
common plant used to treat diabetes mellitus is Hypoxis hemerocallidea (HH). 
The present study was undertaken to investigate the effects of Hypoxis 
hemerocallidea (HH) on T2DM in rats.  
 
Male Wistar rats weighing 200-250 g were used in this experiment. Hypoxis 
hemerocallidea (HH) corm was used as plant material in the experiment. The 
study was based on three parts, an acute diabetes study, chronic diabetes study 
and insulin secretion study. 
 
In the acute study, the rats were randomly divided into 2 groups (control and 
diabetes). The saline solution was added to different concentrations of HH corm 
to produce concentration of (50, 200, 400, 800 mg/ml). Diabetes was induced by 
intraperitoneal injections of STZ (65mg/kg). Two weeks after the injection (STZ 
65 mg/kg), different concentrations of HHS was administered intraperitoneally 
after an overnight fast. The blood glucose levels were monitored in the diabetic 
and control rats at, 30, 60, 120, 180 and 240 minutes post injection. 
 
In the chronic study, the rats were randomly divided into 6 different groups 
(control, HFD, DM, DM-HH, DM-PTHH, and HH). Diabetes mellitus was then 
induced in the groups of diabetic rats by intraperitoneal injections of STZ (40 
mg/kg) and rats were fed a high fat diet (HFD). The body weight of the rats were 
measured weekly for 7 weeks. An intraperitoneal glucose tolerance test (IPGTT) 
was performed at the end of week 6. At the end of week 7, rats were killed and 
serum sample were collected for determination of fatty acid and insulin. Liver and 
 
 
 
 
  
III 
 
pancreatic tissue was collected for histological evaluation. In the insulin secretion 
study, Hypoxis hemerocallidea was tested for its effects on insulin secretion by 
pancreatic islet cells exposed to low (3mM) and high (20mM) glucose medium. 
 
Results of the acute study indicated that HHS at a dose 800 mg/ml decreased 
blood glucose levels fastest in both normal and diabetic rats reaching significance 
after 30 minutes and 60 minutes respectively and remained below the baseline 
value until 240 minutes.  
 
In the chronic study, it was illustrated that HH had no effect in normal rats on any 
of the parameters evaluated. Animals in the DM group gained weight the first two 
weeks, but thereafter began to lose weight. At the end of seven weeks the animals 
gained significantly less weight than the rest. Animals fed a HFD have more 
visceral fat compared to the control group. The visceral fat gain occurred in the 
absence of a significant increase in body weight. We found a markedly lower 
fasting glucose level in HH treated diabetic animals compared to untreated DM 
animals. At time zero the blood glucose level of the HFD group (5.8±0.5mmol/l) 
and the HH group (4.9±0.7mmol/l) were in the normal range, and were not 
significantly different (P > 0.05) from the control group (5.0±0.2mmol/l). After 
glucose load peak blood glucose levels was measured after 30 minutes in the 
control group (9.0±0.6mmol/l), the HFD group (9.8±0.4 mmol/l), the DM-HH 
group (21±5.7 mmol/l) and the DM-HHPT group (27.8±5.3 mmol/l). In the HH 
group the blood glucose level reached a peak at 60 minutes (7.6±0.6 mmol/l). In 
the DM group two peaks were recorded one after 10 minutes (27.2±7.1mmol/l) 
and another after 60 minutes (31±5.2 mmol/l). In the groups control, HFD, DM-
HH, DM-HHPT and HH groups the blood glucose level after 120 minutes were 
not significantly different from the time zero value. The blood glucose level after 
120 minutes in the DM group (28.2±7.1 mmol/L) was significantly higher (P ≤ 0.01) 
than from the time zero value. Serum fatty acid levels were increased in all groups 
fed a high fat diet. The serum insulin levels in the HFD group (6.2 ± 0.76 μUI/ml 
protein; P ≤ 0.05 ), the DM group (2.0 ± 0.9 μUI/ml protein; P ≤ 0.001), the DM-
HH group (3.4 ± 0.7 μUI/ml protein; P ≤ 0.001) and the DM-HHPT group (3.0 ± 
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1.1 μUI/ml protein; P ≤ 0.001) were significantly lower than the control group. 
The β-cell function in the HFD group (62 ± 8 %; P ≤ 0.001), the DM group (3 ± 1 
%; P ≤ 0.001), the DM-HH (11 ± 9 %; P ≤ 0.001) group and the DM-HHPT group 
(4 ± 2 %; P ≤ 0.001) were significantly lower than the control group. The 
histological observation of the liver and the pancreas in rats after 7 weeks on 
different dietary regimes showed some morphological changes within the liver 
and pancreas parenchyma of some rats. 
 
In the insulin secretion study, glucose stimulated insulin secretion in low (3mM) 
and high (2mM) glucose concentration. Furthermore, insulin secretion was 
significantly higher when the glucose concentration was increased from 3mM to 
20 mM (1.10 ± 0.13 μUI/ml protein and 1.5 ± 0.17 mIU/mg protein respectively P 
≤ 0.01). In the presence of low HH (100 µg/ml), there was a marked increase in 
insulin secretion when exposure to high glucose compared to low glucose 
concentration, while in the presence of high HH (500 µg/ml), there was no 
significant different in insulin secretion in the presence of low or high glucose. 
 
In conclusion, the results of this experimental study indicate that a concentration 
800 mg/kg of HHS produces maximal hypoglycaemic effect in fasted normal and 
diabetic rats. HH has an antidiabetic activity as it lowers serum glucose levels in 
T2DM rats and significantly increases glucose tolerance. It also increases body 
weight of diabetic rats. HH treatment was found to improve insulin secretion in 
pancreatic islet cells.  
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CHAPTER I 
 
1 Introduction 
 
Diabetes mellitus (DM) is a condition with an estimated worldwide prevalence, in 2011, 
of 366 million, and a United Kingdom (UK) prevalence of 2.9 million people 
(American diabetes association, 2012). DM is defined as a chronic disease that occurs 
when the pancreas does not produce enough insulin, or when the body cannot 
effectively use the insulin it produces. Hyperglycemia, or raised blood sugar, is a 
common consequence of uncontrolled diabetes and over time leads to serious damage to 
many of the body's systems, especially the nerves and blood vessels (American diabetes 
association, 2012).  
 
There are two main classifications of DM type 1 diabetes mellitus (T1DM) and type 2 
diabetes mellitus (T2DM). T1DM is an auto-immune disease resulting in the destruction 
of pancreatic β-cells. The primary risk factor for T1DM is a genetic predisposition. 
Injury or diseases of the pancreas can inhibit its ability to produce insulin and lead to 
T1DM. A range of relatively rare infections and illnesses can damage the pancreas and 
cause T1DM  (Daneman, 2006). T2DM is strongly associated with obesity and occurs 
as a result of failing pancreatic β-cell function, responsible for the production of insulin, 
often alongside insulin resistance (Chen et al., 2011). 
 
Hypoxis hemerocallidea (HH) is commonly known as African potato is one of Southern 
Africa‘s most common and popular medicinal plants. It is used for a wide a range of 
medical treatments including urinary tract infections, heart disease, infertility and 
anxiety (Brown et al., 2008). It has recently been the subject of several scientific studies 
(Nair et al., 2007). It‘s most popular contemporary use is for prostate disorders for 
which there is increasingly good evidence about its efficacy. Phytosterols are thought to 
be the main bioactive compounds for this indication and also for anti-lipidemic, anti-
diabetic and anti-inflammatory properties exhibited by hypoxis extracts (Boukes et al., 
2008) 
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Despite the popularity of HH as a herbal and botanical medicine, the research into its 
pharmacological application has not been of sufficient depth and width to prove it‘s 
utility in modern medicine (Mahomed & Ojewole, 2003; Boukes et al., 2008). HH has 
been shown to have hypoglycemic effects in both normal and diabetic rats (Mahomed & 
Ojewole, 2003). The mechanism by which the hypoglycemic effect is achieved is 
however not clear.  
 
The plant aqueous extract for HH caused significant reductions in the blood glucose 
levels of the fasted normal and STZ-induced diabetic rats (Mahomed & Ojewole, 2003). 
While it is likely that the hypoglycemic effects of the plant extract are largely due to its 
phytosterols and/or sterolin content, the exact mechanism of its hypoglycemic action is 
still obscure and will have to await further studies (Mahomed & Ojewole, 2003). In a 
study with orally administered aqueous extracts of African potato, Ojewole (2006) 
found significant anti-inflammatory effects in rats, starting at a dose of 50 mg/kg and 
significant antidiabetic effects starting at 100 mg/kg in both normoglycaemic and 
hypoglycaemic rats.  
 
1.1 The purpose of the study 
 
The aim of this study was to investigate the effects of Hypoxis hemerocallidea (HH) on 
type2 diabetes mellitus in rats. In particular, the study seeks: 
 To determine whether HH can control blood glucose levels in diabetes animal 
models. 
 To determine whether HH can increase pancreatic insulin secretion 
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CHAPTER II 
 
2 Literature review 
 
Diabetes mellitus (DM) is one of the most widely known diseases. The word diabetes 
originates from the Greek for `siphon', which means `flow through'. This describes the 
two main symptoms: a great thirst and a need to urinate persistently. The Latin word 
mellitus was later added. It means `honeyed', describing the sugary urine a diabetic 
excretes when the condition is uncontrolled, due to high levels of glucose circulating in  
the bloodstream (Barnett, 2010). 
 
Diabetes has probably been known to medical science longer than any other ailment yet, 
in many respects, it is still poorly understood. It is characterized by  hyperglycaemia 
(high blood glucose) which occurs because the liver and skeletal muscle  cannot store 
glycogen and the tissues are unable to utilize glucose (Tuchman, 2009). Diabetes 
mellitus is caused by the pancreas producing insufficient insulin (Srinivasan et al., 
2008; Roden, 2004). 
 
Diabetic prevalence for all age-groups across the world has been found to be 2.8% in 
2000 and it is speculated that it will increase to 4.4% in 2030 (Wild et al., 2004). It has 
further been speculated that the total number of people with diabetes is projected to rise 
from 171 million in 2000 to 366 million in 2030 (Wild et al., 2004). When considering 
gender, it has been found that men have a higher diabetic prevalence then women (Wild 
et al., 2004). 
 
2.1 Classification of DM 
 
In 1980 the World Health Organisation (WHO) classified diabetes  into type 1 diabetes 
mellitus (T1DM) and  type 2 diabetes mellitus (T2DM) and revised its classification in 
1985 into two types, insulin-dependent diabetes mellitus (IDDM) and non-insulin-
dependent diabetes mellitus (NIDDM) (Ohkubo et al., 1995). The WHO also 
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categorized DM into other types like malnutrition-related diabetes, which is now 
omitted from the new classification due to its unknown aetiology, and diabetes which is 
diagnosed during pregnancy, as gestational diabetes (Alberti & Zimmet, 1998).  
 
2.1.1 Type 1 diabetes mellitus (T1DM) 
 
T1DM is also known as insulin dependent or early onset diabetes and is caused by an 
autoimmune destruction of the islets of Langerhans, resulting in decreased insulin 
production (Adler et al., 2003; D‘Souza et al., 2009). T1DM is becoming a worldwide 
epidemic and evidence suggests that changing environmental factors may be 
responsible. Viral infections, nutritional exposures, perinatal factors, childhood growth, 
and other environmental factors have been explored as potential risk factors for T1DM 
(Maahs et al., 2010; Snell-Bergeon et al., 2010). 
 
2.1.2 Type 2 diabetes mellitus (T2DM) 
 
Formerly called adult-onset diabetes, is the most common type of diabetes affecting 
about 90 % of people with diabetes (Drouin et al., 2009). People can develop T2DM at 
any age, even during childhood, but this type of diabetes is most often associated with 
age (Adler et al., 2003; Chen et al., 2011). T2DM is also associated with obesity, 
physical inactivity, a family history of diabetes, previous history of gestational diabetes, 
and ethnicity (Committee and Classification, 2010; Pickup, 2004). The pancreas in 
T2DM  loses its ability to produce enough insulin in response to meals, and blood 
glucose levels rise (Marshall et al., 1991; Nyman et al., 2011). 
 
2.2 Symptoms of DM 
 
Both T1DM and T2DM have similar symptoms. However, as for T1DM the symptoms 
develop more rapidly in days or weeks. These symptoms include polyuria, polydipsia, 
unexplained weight loss, muscle wasting, fatigue, cramps, constipation, blurred vision 
and skin infections. Long term complications caused by DM include microvascular and 
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nephropathic  disease, and are the major causes of morbidity and mortality in DM 
patients (Wolfs et al., 2009; Song & Hardisty, 2008; Ahmed, 2005). 
 
Hypoglycaemia is the limiting factor in the glycaemic management of diabetes. 
Hypoglycaemia is a result of the interplay of insulin excess and compromised glucose 
counter regulation in T1DM (Graveling & Frier, 2009) caused by over medication, 
excessive exogenous insulin and strenuous exercise. It may lead to seizures, coma and 
irreversible brain death as blood glucose regulates the functioning of the body organs, 
including the brain. Symptoms due to hypoglycaemia include irritability, sweating, 
tingling lips, weakness, hunger and nausea (Cryer, 2002; McAulay et al., 2001). 
 
Hyperglycaemia is a result of increased blood glucose levels.  This can be caused by 
factors such as  not taking medication, exogenous insulin, an imbalanced diet or a lack 
of  exercise (Dungan et al., 2009). It may also occur due to autoimmune destruction of 
β-cells in the pancreas. Lack of insulin causes ketoacidosis when ketones are released 
into the blood causing a rise in the plasma acidity levels.  Both hypo and 
hyperglycaemia are reversible and can be treated (Luitse et al., 2012; Ahmed, 2005). 
 
2.3 Complications associated with DM 
 
Persistent high blood glucose levels could result in the glycosylation of proteins 
resulting in the irreversible damage of tiny blood vessels and nerve endings in the areas 
furthest from the heart, retina, renal glomerulus such as  the nerve sheath and the 
cellular membranes (Deshpande et al., 2008). 
 
Macrovascular complications (which affect the larger blood vessels in the body), are 
common among T2DM patients. These patients are more likely to suffer from 
hypertension and coronary heart diseases (CHD) including, atherosclerosis and 
thrombosis. About 75% of macrovascular diabetic mortality is due to coronary heart 
disease. Figure 2.1 shows the most important organs affected by diabetes. 
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2.4 Epidemiology of DM 
 
According to the WHO, 180 million people have been estimated to suffer from T2DM 
in 2006 and the annual death rate due to this disease was 3 million at that time. Both 
numbers are expected to double over the next 25 years (Wolfs et al., 2009). An 
interesting fact about T2DM is that the prevalence of this disease varies widely among 
various racial and ethnic groups as shown in figure 2.2 below (Selvin et al., 2011), 
which suggests that a genetic component plays a pivotal role in the disease 
development. 
 
 
Figure ‎2.1. The organs affected by diabetes complication (Adapted from Deshpande 
et al., 2008). 
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Figure ‎2.2. Prevalence of Diabetes by Race/Ethnicity in the United States (Adapted 
from Kappala, 2012). 
 
The prevalence of T1DM is approximately 1 in 300 in the US by 18 years of age (Wild 
et al., 2004). Research on risk factors for T1DM is an active area of research to identify 
genetic and environmental triggers that could potentially be targeted for intervention. 
While significant advances have been made in the clinical care of T1DM with resultant 
improvements in quality of life and clinical outcomes, much more needs to be done to 
improve care of diabetes,  and to ultimately find a cure for T1DM. Epidemiologic 
studies have an important on-going role to investigate the complex causes, clinical care, 
prevention, and cure of T1DM (Lamb et al., 2008; Snell-Bergeon et al., 2010). 
 
2.5 Diagnosis of DM 
 
There was major perplexity regarding the criteria for diagnosis of DM before the 1970s. 
The WHO has put forward its first statement on the diagnosis of DM in 1965, which 
was later tailored and made simple. The American Diabetes Association (ADA) 
proposed its first diagnostic criteria, which emphasised the concentration of fasting 
glucose. Figure 2.3 shows a flow diagram for the diagnosis and screening of DM 
including Glucose Tolerance Test (GTT) (Kappala, 2012). A report by the WHO 
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recommends glycated haemoglobin (HbA1c) as an additional test to diagnose diabetes 
(Association, 2006) . 
 
 
 
 
Figure ‎2.3. Diagnosis and screening for diabetes and impaired glucose 
metabolism (Adapted from Kappala, 2012). 
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2.6 Pathogenesis of DM 
 
T1DM produces profound β-cell failure with secondary insulin resistance, whereas 
T2DM is associated with less severe insulin deficiency but greater impairment of 
insulin action. Given their similarities overall, it is not surprising that the two major 
forms of diabetes share many pathophysiologic features. Despite the apparent 
phenotypic similarity, the underlying pathogenic mechanisms leading to T1DM and 
T2DM are strikingly different. T1DM most likely results from an interplay of genetic, 
environmental, and autoimmune factors. Figure 2.4 shows a modern model of the 
pathogenesis and natural history of T1DM. The modern model expands and updates the 
traditional model by inclusion of information gained through an improved 
understanding of the roles for genetics, immunology, and environment that selectively 
destroy insulin-producing β-cells (Atkinson, 2012).  
 
 
Figure ‎2.4. Summary of the sequence of events that lead to pancreatic 
β-cell loss and ultimately to the clinical evolution of type 1 diabetes  
(Adapted from Atkinson, 2012). 
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The two main reasons underlying the pathophysiology of T2DM are impaired insulin 
secretion due to the dysfunction of pancreatic beta cells and impaired insulin action 
because of insulin resistance (DeFronzo, 2004). A breakdown of these two mechanisms 
consequently results in abnormally high levels of plasma glucose concentrations that are 
usually maintained in a definite range irrespective of the various changes for the 
requirement and supply which is regulated by a dynamic process between tissue 
sensitivity and insulin (Esmaillzadeh et al., 2007). Figure 2.5 shows T2DM results from 
an array of dysfunctions characterized by hyperglycemia and results from the 
combination of resistance to insulin action, inadequate insulin secretion, and excessive 
or inappropriate glucagon secretion (Meshkani & Adeli, 2009) . 
 
Inflammation and inflammatory cytokines have been suggested to be the reason for the 
development of T2DM. Insulin resistance develops from physical inactivity (Kahn, 
1998).  Insulin resistance is commonly accompanied by other cardiovascular risk factors 
like dyslipidaemia, hypertension and pro-thrombotic factors These factors together in an 
individual are called the metabolic syndrome, which precedes T2DM (Inzucchi et al., 
2012; DeFronzo, 2004).    
 
 
 
 
Figure ‎2.5. Simplified scheme for the pathophysiology of type 2 diabetes mellitus  (Adapted 
from Kappala, 2012). 
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2.7 Treatment of DM 
 
Individuals suffering from T1DM are insulin dependent. Insulin are normally injected 
8* different forms, like fast affecting insulin, which is vastly absorbed. The structural 
difference between normal human insulin and the synthetic form of insulin is the 
conversion or replacement of few amino acids to slow down its absorption or to extend 
its action. Rapid insulin has to be given at eating period. While, short effecting insulin is 
exerting its effect within one hour after subcutaneous injection. While long acting 
insulin may act for more than twelve hours. 
T2DM treatment depends mostly on different hypoglycaemic drugs (Ganesh et al., 
2010). There are about five categorizes of available drugs. Sulfonylureas show their 
hypoglycaemic effect through enhancing insulin release from pancreatic β-cell. The 
mechanism of action of sulfonylureas is via its binding with ATP-sensitive potassium 
channels and thus preventing the release of potassium from the cell leading to influx of 
calcium via the voltage-dependent calcium channels. The elevated cytoplasmic calcium 
levels lead to the secretion of insulin. Meglitinide is a non-sulfonylureas drug that is 
linked to different β-cell receptors promoting a similar action to sulfonylureas in 
enhancing insulin secretion (Ganesh et al., 2010). 
Metformin is one of the biguanides anti-diabetic drug categories and it exerts its effect 
by inhibiting glucose release from the liver via suppressing gluconeogenesis and 
glycolysis. Metformin does not lead to a condition of hypoglycaemia since it has no 
effect on insulin release (Ganesh et al., 2010). Thiazolidine increases glucose entrance 
into different tissues including skeletal muscle (Oiknine, and Mooradian, 2003). A last 
class of anti-diabetic drugs is the α-glycosidase inhibitors like miglitol and acarbose. 
Their effect is mainly through postponing carbohydrate absorption in the epithelial cells 
in the lining wall of the small intestine (Oiknine, and Mooradian, 2003). 
 
2.8 Animal models for DM 
 
Typically animals have been used intensively in DM research. Early studies used 
pancreatectomized dogs to confirm the pivotal role of the pancreas in glucose 
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homeostasis, crowned in the discovery and purification of insulin. Today animal 
experimentation is contentious and subject to restriction and ethical restrictions that 
vary all over the world. Most experiments are carried out on rodents, however some 
studies are still performed on larger animals. Several toxins, including alloxan and 
streptozotocin   are used to stimulate hyperglycaemia in rats and mice (Coskun et al., 
2005). Selective breeding has produced many strains of animals that are considered 
reasonable models of Type 1 diabetes, Type 2 diabetes and related phenotypes such as 
obesity and insulin resistance. Out of their use in researches the pathogenesis of the 
disease and its complications, all new treatments for diabetes, including islet cell 
transplantation and precaution strategies, were originally achieved in animals. In recent 
years, molecular biological techniques have produced a large number of new animal 
models for the study of diabetes, including knock-in, generalized knock-out and tissue-
specific knockout mice (Rees & Alcolado, 2005). 
 
2.8.1 Models for T1DM 
 
The main feature of T1DM is an autoimmune destruction of the β-cell, causing to lack 
of insulin production. In animal models for T1DM, this defect in insulin production is 
achieved using a variety of different mechanisms, ranging from chemical ablation of the 
beta cells to breeding rodents that spontaneously evolve autoimmune diabetes (King, 
2012; Rees & Alcolado, 2005). Some of the most commonly used models of T1DM are 
outlined in Table2.1 (King, 2012). 
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Table ‎2.1. Summary of rodent models of type 1 diabetes ( Adapted from King, 2012). 
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2.8.2 Models for T2DM 
 
T2DM is caused by insulin resistance coupled by a failure of the beta cell to compensate 
insulin secretion, therefore, typical animal of T2DM tend to include models of insulin 
resistance or models of β-cell dysfunction. Many T2DM animal models are reflecting 
the human condition and are obese, since obesity is closely related to T2DM 
development (King, 2012; Rees & Alcolado, 2005). Some of the most commonly used 
models for T2DM are outlined in Table 2.2 (King, 2012). 
 
Animal models have dramatically contributed to the researches of T2DM. Most 
researcher is carried out on rodents, despite that the other species with human-like 
biological characteristics are also used. Animal models develop T2DM, either 
automatically or by using surgical, chemical,  genetic or other techniques, and describe 
many clinical features or related phenotypes of the disease (Chatzigeorgiou et al., 2009; 
Srinivasan & Ramarao, 2007). The combination of HFD fed and low-dose STZ treated 
rat serves as an alternative animal model for T2DM simulating the human syndrome 
that is also suitable for testing anti-diabetic agents for the treatment of T2DM 
(Srinivasan et al., 2005). 
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Table ‎2.2. Summary of rodent models of type 2 diabetes ( Adapted from King, 2012). 
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2.9 The Pancreas 
 
The pancreas is a retroperitoneal secretory organ and the pancreas secretes several 
hormones including insulin and glucagon (Nobukawa, 2007). It is critical to the 
production of insulin and glucagon which regulate glucose levels in the blood. 
(Gromada et al., 2007). 
 
2.9.1 Anatomy of the Pancreas 
 
The humans pancreas is found posterior to the stomach, in the curve of the duodenum 
which is the first part of the small intestine. It is a 12-15–cm long, soft, lobulated and 
weighs between 70-110 grams (Coales, 2000). 
 
The structure of a pancreas includes a head, uncinate process, neck, body and tail. The 
head lies within, and closely attached to the ‗C‘ of the duodenum. The main pancreatic 
duct (Wirsung) runs the length of the gland. It usually joins the common bile duct at the 
ampulla of Vater to enter the second part of the duodenum at the duodenal papilla 
(Horiguchi & Kamisawa, 2010) (Figure 2.6).  
 
 
Figure ‎2.6. Diagramme of the Pancreas in situ ( Adapted from Heijerman et al., 1991). 
 
 
 
 
  
17 
 
The accessory duct (Santorini) opens into the duodenum proximal into the main duct. 
The gland is lobulated and produces the exocrine secretion of digestive hormones from 
serous-secreting cells, arranged in alveoli. Between these lie the islets of Langerhans, 
containing α-cells (glucagon secreting cells), β-cells (insulin secreting cells) and δ-cells  
(gastrin and somatostatin secreting cell) (Nobukawa, 2007). The arterial supply occurs 
through the splenic artery. The corresponding veins channel into the portal system. The 
splenic artery is characteristically tortuous and runs along the upper border of the 
pancreas; the vein lies behind the gland. Embryologically, the pancreas derives from a 
large dorsal diverticulum from the duodenum and a small ventral bud from the side of 
the bile duct. The ventral bud swings posteriorly to fuse with the dorsal, trapping the 
superior mesenteric vessels between hence forming the uncinate process. The ducts of 
the two buds communicate, which of the ventral bud takes over the main duct, leaving 
the original duct of the larger dorsal bud as the accessory duct (Ellis, 2007). 
 
2.9.2 Histology of the Pancreas 
 
The pancreas contains tissue with an endocrine and exocrine role, and this division is 
also visible when the pancreas is viewed under a microscope. The tissues with 
an endocrine role can be seen as lightly-stained clusters of cells, called islets of 
Langerhans (Young et al., 2006). 
 
Darker-staining cells form clusters called acini, which are arranged in lobes separated 
by a barrier. The secretory cells of each sinus surround a small intercalated duct. As a 
result of their secretory function, these cells have many small granules of zymogens that 
are visible. The intercalated ducts drain into larger ducts within the lobule, and 
eventually interlobular ducts. The ducts are lined by a single layer of columnar cells. 
With an increase in cells diameter, several layers of columnar cells may be seen (Young 
et al., 2006). 
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Figure ‎2.7. Schematic representation of islets of Langerhans 
embedded in the exocrine parenchyma ( Adapted from 
Cendrowski, 2013). 
 
 
The islets of Langerhans (Figure 2.7) consist of insulin- releasing β-cells (65-90%) 
forming the core of the islet, glucagon-releasing α-cells (15-20%), somatostatin-
producing δ-cells (3-10%), and pancreatic polypeptide-producing PP-cells (1%) are 
usually located on the surface (Elayat et al., 1995). Of these, β-cells, which couple 
nutrient metabolism with electrical activity to modulate the synthesis and release of 
insulin, have been most frequently studied. The islets of Langerhans play an imperative 
role in glucose metabolism and regulation of blood glucose concentration (Jo et al., 
2007). 
 
2.9.3 Hormones Secreted by Pancreas 
 
 Insulin 2.9.3.1
 
Insulin is a small protein composed of two polypeptide chains containing 51 amino 
acids (Aronoff et al., 2004). The primary action of insulin is to reduce blood glucose 
concentration. Beta cells can respond quickly to spikes in blood glucose concentrations 
by secreting some of their stored insulin while simultaneously producing more (Wilcox, 
2005). 
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Insulin is synthesized in the ribosomes of the rough endoplasmic reticulum as 
preproinsulin which is the cleaved to proinsulin. Proinsulin is transported to the Golgi 
apparatus where it is packaged into secretory granules located close to the cell 
membrane. Proinsulin is cleaved into equimolar amounts of insulin and C-peptide in the 
secretory granules. The process of insulin secretion involves fusion of the secretory 
granules with the cell membrane and exocytosis of insulin and C-peptide Figure 2.8 
(Skelin et al., 2010).  
 
 
Figure ‎2.8. Insulin biosynthesis ( Adapted from Skelin 
et al., 2010). 
 
 
 
 Insulin Secretion 2.9.3.1.1
 
Glucose transporter two (GLUT2), the facilitative glucose transporter isoform expressed 
in pancreatic beta cells, is believed to play a role in glucose-stimulated insulin secretion. 
GLUT2 are a large group of membrane proteins that facilitate the transport of glucose 
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over a plasma membrane (Figure. 2.9) (Röder et al., 2014; Guillam et al., 2000). 
Glucose phosphorylation by glucokinase is the rate-limiting step that controls glucose-
regulated insulin secretion. Further metabolism of glucose-6-phosphate via glycolysis 
generates Adenosine triphosphate (ATP) (Teague et al., 2011). 
 
 
 
 
Figure ‎2.9. Glucose stimulated insulin secretion in pancreatic β-
cells ( Adapted from Teague et al., 2011). 
 
 
 
Potassium (K
+
) channels consist of two separate proteins: one is the binding site for 
certain oral hypoglycemics (e.g., sulfonylureas, meglitinides); the other is an inwardly 
rectifying K
+ 
channel protein. Inhibition of this K
+
 channel induces beta cell membrane 
depolarization, which opens voltage-dependent calcium channels (leading to an influx 
of calcium), and stimulates insulin secretion. Insulin secretory profiles reveal a pulsatile 
pattern of hormone release, with small secretory bursts occurring about every 10 
minutes, superimposed upon greater amplitude oscillations of about 80–150 minutes. 
Incretins are released from neuroendocrine cells of the gastrointestinal tract following 
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food ingestion and amplify glucose-stimulated insulin secretion and suppress glucagon 
secretion (Lee, 2001).  
 
Glucagon-like peptide 1 (GLP-1), the most potent incretin, is released from L cells in 
the small intestine and stimulates insulin secretion only when the blood glucose is above 
the fasting leve (Maechler & Wollheim, 2000). 
 
 Insulin resistance  2.9.3.1.2
 
In insulin resistance, muscle and fat do not respond properly to insulin and thus cannot 
easily absorb glucose from the bloodstream. As a result, the body needs higher levels of 
insulin to help glucose enter cells, the β-cells in the pancreas try to keep up with this 
increased demand for insulin by producing more (Giugliano et al., 2008; Wilcox, 2005). 
The pathophysiology of insulin resistance involves a complex network of signalling 
pathways, activated by the insulin receptor, which regulates intermediary metabolism 
and its organization in cells (Giugliano et al., 2008). 
 
  C-peptide 2.9.3.2
C-peptide is secreted into the blood in equimolar quantities to insulin and helps to 
prevent neuropathy and other vascular deterioration related symptoms of diabetes 
mellitus (Wahren et al., 2000). 
 
 Amylin 2.9.3.3
Amylin is also known as islet amyloid polypeptide (IAPP). The function of amylin is to 
slow the rate of glucose entering the bloodstream. Amylin can be described as a 
synergistic partner to insulin, where insulin regulates long term food intake and amylin 
regulates short term food intake (Bennett et al., 2003). 
 
Amylin and insulin are co-localized within the same secretory granules of pancreatic β-
cells. Amylin is also found in much lesser quantities in the gut and other tissues (Young, 
2005). 
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2.10 Medicinal plants used for diabetes mellitus 
 
Around 400 herbal medicines used to treat many diseases such as diabetes mellitus have 
been reported, but only a small number of these plants have received scientific and 
medical evaluation to assess their efficacy (Kavishankar, 2011). Traditional treatments 
are prescribed by practitioners of alternative medicine or sometimes taken by patients as 
supplements to conventional therapy (Arumugam et al., 2013). Herbal medicine 
remedies are the mainstay of treatment in underdeveloped regions. (Arumugam et al., 
2013). The hypoglycemic action of some treatments has been confirmed in animal 
models and non-insulin-dependent diabetic patient A botanical substitute for insulin 
seems unlikely, but herbal medicine may provide many clues for the development of 
new oral hypoglycemic agents and simple dietary adjuncts (Kavishankar, 2011; 
Arumugam et al., 2013). 
 
Table ‎2.3. Medicinal plants with antidiabetic and their reported effect on experimental models ( 
Adapted from Kavishankar, 2011). 
 
Botanical Name Family Antidiabetic and other beneficial 
effects 
Achilieasantolina[L Asteraceae Hypoglycemic, antioxidant 
Artemisia patterns Asteraceae Hypoglycemic, increases peripheral 
glucose utilization 
Areca catechu L.  Arecaceae Hypoglycemic 
Beta vulgaris L.  Chenopodiaceae Increases glucose tolerance in OGTT 
BoerhaaviadiffusaL.  Nyctaginaceae Decreases blood glucose level and 
increases plasma insulin levels, 
antioxidant 
BombaxceibaL.  Malvaceae Hypoglycemic 
Butea manosperma(Lam)  Caesalpinaceae Anti-hyperglycemic 
CarumcarviL. 
CapparisspinosaL. 
Apiaceae 
Capparidaceae 
Potent anti-hyperglycemic 
CogniauxiapodoleanaBaillon 
Bail Ion 
Cucurbitaceae Hypoglycemic and anti-
hyperglycemic 
CommelinacommunisL Conimelinaceae Anti-hyperglycemic, management of 
non-insulin-dependent diabetes. 
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Croton cajucaraBenth Euphorbiaceae Anti-hyperglycemic 
Curcuma longa L.  Zingiberaceae Hypoglycemic, plays a role in PPAR-
gamma activation 
Cynodondactylon Pers Poaceae Anti-hyperglycemic 
Enicostemmalittorale Blume  
 
Gentianaceae Decreases plasma glucose level, 
glycosylated haemoglobin and 
glucose-6-phosphatase activity in 
liver 
Eriobotrya japonica  Lindl. RosaceaeHypoglycemic 
GentianaolivieriL.  Gentianaceae Hypoglycemic, anti-hyperlipidemic 
Ginkgo bilobaL.  Ginkgoaceae Hypoglycemic, increases pancreatic 
beta-cell in NIDDM 
GlobulariaalypumL.  Globulariaceae Hypoglycemic, increases plasma 
insulin levels 
GlycyrrhizauralensisFish.  Papilionaceae PPAR-gamma ligand-binding 
activity, decreases the blood glucose 
levels 
GymnemanwntanumHook 
 
Asclepiadaceae Anti-peroxidative, antioxidant, may 
prevent the cholinergic neural and 
retinal complications of 
hyperglycemia in diabetes 
GymnemasylvestreR. Br.  Asclepiadaceae Hypoglycemic. Hypolipidemic 
Hintoniastandleyana Rubiaceae Anti-hyperglycemic 
IbervilleasonoraeS.  Cucurbitaceae Acute and chronic hypoglycemic 
Ipomoea aquatic Forsk.  Convolvulaceae Decreases serum glucose 
concentration by 29.4% in Type II 
diabetic patients. hypoglycemic 
Kalopanaxpictus 
 
Thumb. Araliaceae 
 
Anti-diabetic activity, 
hypocholesterolmic and 
hypolipidemic 
Lagerstroemia speciosaL.  Lythraceae Insulin-like actions, glucose uptake, 
anti-adipogenesis 
Medicago saliva L.  Fabaceae Anti-hyperglycemic, insulin-releasing 
and insulin-like activity 
Morus alba L.  Moraceae Protects pancreatic beta cells from 
degeneration anddiminishes lipid 
peroxidation 
Morusindica. L.  Moraceae Hypoglycemic 
MorusinignisL. Moraceae Hypoglycemic 
MurrayakoenigiiL.  Rutaceae Hypoglycemic, increases 
glycogenesis,decreases 
gluconeogenesis and glycogenolysis 
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NelumbonuciferaL.  Neluntbonaceae Improves glucose tolerance and 
potentiates the action of 
exogenouslyinjected insulin 
Nigella saliva Gaertn. Ranunculaceae Decreases oxidative stress and 
preserves pancreatic beta-cell 
integrity 
Ocimumgratissinuim L. Var. Lamiaceae Hypoglycemic 
Pandanus odorusRidl Pandanaceae Hypoglycemic, increases serum 
insulin levels and liver glycogen 
ParmentieruedulisA.DC  Bignoniaceae Hypoglycemic 
Phyllanthussellowianus 
Mull.Arg. 
Euphorbiaceae Hypoglycemic 
Psacaliumdecompositum(Gray) 
H. 
Asteraceae Hypoglycemic 
Psacaliumpeltatum(Kunth)  Asteraceae Anti-hyperglycemic 
PunicagranatumL.  
 
Punicaceae Improves postprandial hyperglycemia 
in type 2 diabetes and obesity by 
inhibiting intestinal alpha-glucosidase 
activity 
Solaria oblonga 
 
Celastraceae Hypoglycemic and possess anti-
oxidant activity 
SambucusnigraL.  
 
Adoxaceae Insulin-releasing and insulin-like 
activity 
Sanguisdraxonis Apocynaceae Increase insulin sensitivity and 
improve the  development of insulin 
resistance in rats 
Sclerocaryabirea(A.Rich)  Anacardiaceae Hypoglycemic 
ScopariadulcisL.  Scrophariaceae Hypoglycemic, antihyperlipidemic, 
antidiabetic 
Swertiachirayita(Roxb)  Gentianaceae Stimulates insulin release from islets 
Syzygiumalternifolium(Wt) 
Walp. 
Myrtaceae Hypoglycemic, antihyperglycemic 
and antihyperlipidemic 
Terminalia bellirica(Gaertn)  Combretaceae Stimulates insulin secretion. 
Enhances insulin action andinhibits 
both protein glycation and starch 
digestion. 
Terminalia chebulaRetz.  
 
Combretaceae Dose-dependent glucose lowering 
effect, antidiabetic and 
renoprotective,decreases hepatic and 
skeletal muscle glycogen content, 
increases insulin release from the 
pancreatic islets 
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Teucriumpolium Lamiaceae Increases insulin release, antioxidant 
and hypoglycemic 
TinosporacordifoliaMiers.. Menispermaceae Hypoglycemic 
Tinosporacrispa(L) Hook.  Menispermaceae Anti-hyperglycemic, stimulates 
insulin release from islets 
UrticadioicaL.  Urticaceae Anti-hyperglycemic 
UrticapiluliferaL.  Urticaceae Hypoglycemic 
VincaroseaL.  Apocynaceae Anti-hyperglycemic 
Withaniasoimifera(L) Dunal Solanaceae Hypoglycemic, antioxidant, diuretic 
and hypocholesterolemic 
WithaniacoagulansDunal Solanaceae Anti-hyperglycemic, anti-
hyperlipidemic and hypoglycemic 
ZizyphussativaGaertn Rhamnaceae Hypoglycemic 
Zizyphusspina-christiL RhamnaceaeInsulinotropic, hypoglycemicanddepressant effect on 
the central nervous system 
ZygophyllumgaetulumEmb Zygophyllaceae Hypoglycemic, increases plasma 
insulin levels 
 
 
2.11 Hypoxis hemerocallidea (HH) 
 
Hypoxis hemerocallidea (HH)  is  more commonly known as hypoxis, African potato 
(AP), Hypoxis rooperi, Yellow star flower (English), Inkomfe (Zulu) and Lilabatseka, 
Zifozonke (Swazi) (Nicoletti et al., 1992). 
Hypoxis hemerocallidea (HH) is one of southern Africa‘s most important and popular 
medicinal plants (Nicoletti et al., 1992). HH has a long history of traditional use for a 
diversity of ailments and more recently has been the subject of several scientific studies. 
In many parts of Africa the corms of this attractive yellow flowered herb have been 
used in the treatment of urinary tract diseases, prostate hypertrophy and cancer 
(Mahomed & Ojewole, 2003). 
HH is geophytic and overcome winter conditions in the form of an underground 
rootstock called a corm. It also has adventitious roots attached to the corms that are 
thick, fleshy and which arise from the base of young corms. The flowering stems are 
unbranched, with 2-12 flowers per stalk. Flowers are symmetrical with 6 petals, which 
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are bright yellow, giving the plant its common name Yellow Stars, shown in Figure 2.10 
(Nair, 2006; Nair & Kanfer, 2006). 
 
 
 
Figure ‎2.10. Photograph of a Young Corm of Hypoxis 
hemerocallidea ( Adapted from Nair, 2006). 
 
 
 
 
The corms of these plants are graded on size. The small (200 g) corms are generally 
from one year old seedlings and the medium (450 g) corms are at least three years old 
whereas the large corms (800 g) are older. The fleshy corms of HH are yellow in colour 
in the inside, but soon turn to dark brown because of oxidation, when exposed to air 
(Figure: 2.11.) (Nair, 2006). 
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Figure ‎2.11. Photograph of the Tran-section of a 
Corm of Hypoxis hemerocallidea ( Adapted from Nair, 
2006). 
 
 
2.11.1 Geographical distribution 
 
HH is widely distributed all over the world, with reports of existence in various 
countries including South Africa, New Zealand, Malawi, Madagascar, Mauritius, 
Mozambique, America, Zimbabwe and other Central Africa countries (Street & 
Prinsloo, 2013; Mogatle, 2008).  
 
In South Africa, all of  the genus is distributed in the provinces KwaZulu-Natal, 
Limpopo, Eastern Cape, Mpumalanga, and Gauteng (Singh, 2007). 
 
2.11.2 Traditional use 
 
The corm of  HH has been used in folk medicine to treat  different diseases which 
include the common cold, flu, hypertension, adult-onset diabetes, psoriasis, urinary 
infections, testicular tumours, prostate hypertrophy, cancer and HIV/AIDS (Laporta et 
al., 2007; Nair & Kanfer, 2006). Table 2.4 shows the most important traditional uses of 
HH (Mogatle, 2008). 
 
Table ‎2.4. Traditional uses of HH ( Adapted from Mogatle, 2008) 
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Reported Use Part of 
plant 
Preparation Area 
Diabetes Corms Fresh corms boiled  
and  taken orally 
Eastern Cape 
South Africa 
Prostate 
Hypertrophy 
 
NS* 
 
NS* Maputo 
Mozambique 
Urinary or 
venereal 
Diseases 
NS* NS* KwaZulu Natal 
South Africa 
Cancer 
 
Corms Pulverised corms are boiled  
and taken orally 
Eastern Cape 
Southern Africa 
Wound 
management 
Leaves 
corms 
Dry powder  sprinkled on wounds,  
Fresh or dried Material extracted  
and used as wash 
Eastern Cape 
South Africa 
HIV/AIDS 
management 
NS* NS* Johannesburg, 
South Africa 
*NS – not stated. 
 
 
2.11.3 Phytochemistry and biological activity 
 
The use of HH could be attributed to a few of the medicinal agents found in the plant of 
which hypoxoside, sitosterol, and its aglycone derivative rooperol are the most well-
known compounds (Street & Prinsloo, 2013). Hypoxoside is the trivial name for (E)-
1,5bis (4′-B-D-glucopyranossyloxy-3′-hydroxyphenyl) pent-1-en-4-yne which is a 
norlignan diglucoside isolated from the rootstock of the family Hypoxidaceae. In 
addition to hypoxoside and rooperol, the root stocks are reported to contain 𝛽𝛽-
sitosterols, sterol, monterpeneglycosides, stanols, and stigmastanols (Laporta et al., 
2007). The result of the chemical analysis of HH showed that the species have different 
classes of secondary metabolites, namely, glycosides, polyphenols, saponnins, steroids 
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and tannins. The rootstock of HH has yielded three cytokinins, identified as zeatin, 
zeatin riboside, and zeatin glucoside (Street & Prinsloo, 2013). The high concentration 
of phytosterols such as 𝛽𝛽-sitosterols has proven to be effective against benign prostate 
hypertrophy (Steenkamp, 2003), and a strong decoction of the rootstocks is also used as 
purgatives (Mills et al., 2005). Rooperol may be obtained by treating hypoxoside with a 
𝛽𝛽-glucosidase remove the attached glucose groups. 𝛽𝛽-glucosidase is an enzyme 
found predominantly in the gastrointestinal tract (Mills et al., 2005). While it is likely 
that the hypoglycemic effect of the plant extract is largely due to its phytosterols or 
sterolin content, the exact mechanism of its hypoglycemic action is still obscure and 
will have to await further studies (Nair, 2006; Street & Prinsloo, 2013). 
 
2.11.4 Toxicity 
 
A lethal dose (LD50) in mice was found to be 1948 ± 57 mg/kg of HH aqueous extract 
after oral administration (Ojewole, 2006). The LD50 of HH aqueous extracts after oral 
administration in mice 1948 ± 57 mg/kg as a lethal dose.  Lower dose at (≤ 1600 mg/kg) 
of HH aqueous extracts is safe while relatively higher doses were toxic and/or lethal to 
the mice (Ojewole, 2006). 
 
HH when infused in anaesthetized chacma baboons had no effect on the cardiovascular 
system. The cardiac output increased together with systemic and pulmonary arterial 
pressures and these changes were not accompanied by changes in heart rate, vascular 
resistances or in the filling pressures of the heart (Albrecht & Theron et al., 1995). 
 
.One should also bear in mind that the traditional use of the HH plant goes back a long 
time, this in itself constitutes a form of clinical trial, since evidence of toxicity would 
have led to its abandonment by traditional healers long ago. It is of interest to note that 
Vahrmeijer, 20 in his book Poisonous Plants of Southern Africa, makes no mention of 
Hypoxis species(van Wyk, 2008). 
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2.11.5 Registered Patents 
Several patents of Hypoxis, hypoxoside, rooperi and rooperol have been registered in 
the Europe and the USA (Mogatle, 2008). A patent registered under the title ―method of 
treating viral infections‖ was registered by Liebenberg .  The patents include methods of 
extraction and preparation of derivatives (Mogatle, 2008). 
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CHAPTER III 
 
3 Materials and Methods 
 
3.1 Materials 
 
3.1.1 Chemicals and Drugs 
 
All the chemicals used in the study were of standard grade. Ethanol, xylene , glucose, 
fructose and formaldehyde were obtained from Merck Chemicals Sodium citrate, 
sodium chloride (NaCl) and calcium chloride where purchased from Kimix 
Laboratories, South Africa. The sodium phosphate (NaHPO4), sodium dihydrogen 
phosphate (NaH2PO4), streptozotocin (STZ), casein, cholesterol, histopaque and 
collagenase XI were obtained from Sigma-Aldrich. Hank‘s balanced salt solution 
(HBSS), Roswell Park Memorial Institute-1640 medium (RPMI 1640), L-glutamine, 
Penicillin–streptomycin and Fetal bovine serum (FBS) were obtained from GIBCO. 
Phosphate buffered salin (PBS) was obtained from Lonza and cooking fat (HUDSON & 
KNIGHT) was obtained at a local supermarket. 
 
3.1.2 Instrument and Equipment 
 
This is listed equipment used in these experiments: 
 Glucose meter )Contour TS). 
 Glucose strip )Contour TS(. 
 Tissue baths. 
 Automated Leica TP 1020 tissue processor. 
 Vacuum system. 
 Microtome (Leica 2125 RT). 
 GloMax Multi Detection System plate reader. 
 water bath 
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 Centrifuge (Eppendorf, 5810R). 
 Dissecting microscope. 
 50-ml sterile tube (SPL Life sciences supply). 
 96 sterile well plates (SPL Life sciences supply). 
 Test tube 15cm-50cm (SPL Life sciences supply). 
 Sterile pipittes 10ml (SPL Life sciences supply). 
 25-ml sterile pipettes (SPL Life sciences supply). 
 200 μl sterile pipette (SPL Life sciences supply). 
 100 mm Petri-dishes (SPL Life sciences supply). 
 Filter paper (240nm thick). 
 
3.2 Animals 
 
Male Wistar rats were used in this experiment. Rattus norvegicus (Wistar rats) weighing 
200–300g were obtained from the University of Stellenbosch, South Africa and housed 
in the Medical Bioscience Department, University of the Western Cape, in a 
temperature controlled room (23±1°C) with a 12-hour light dark cycle. Light hours were 
from 08h00 to 20h00 and dark hours from 20h00 to 08h00. The rats received food and 
water ad libitum during a 2-week acclimatization period.  
 
3.3 Plant Material 
 
The plant materials used in this experiment was Hypoxis hemerocallidea (HH) corm 
purchased, which was purchased from Global Fusion Trading  Cape Town- South 
Africa. 
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3.4 Acute Studies 
 
3.4.1 Experimental Protocol 
 
 
 Preparation of Hypoxis hemerocallidea solution (HHS) 3.4.1.1
  
The saline solution was added to different concentrations of HH corm (50, 200, 400, 
800 mg/ml). Thereafter, it was filtered through a cheese cloth and what man filter paper 
(no 4 and 1 respectively) using a vacuum system and subsequently also using syringe 
filter (0.22 µm). The HHS was allowed to cool at room temperature and then 
intraperitoneal injected into the rats. 
 
 Treatment Protocol 3.4.1.2
 
The rats were randomly divided into 2 groups, with eight animals assigned to each 
group (n=8) and each group housed in separate cages.  
Group (1), control group: the rats in this group were fed the normal laboratory pellets.  
Group (2), Diabetes group (DM): the rats in this group were injected with streptozotocin 
(STZ) 65 mg/kg to induce diabetes mellitus and fed the normal laboratory pellets. 
 
 Parameters Assessed 3.4.1.3
 
Two weeks after STZ injection (65 mg/kg), the blood glucose levels were monitored in 
all the rats using a handheld Contour TS blood glucose meter. Rats were anaesthetized 
with sodium pentobarbital (50 mg/kg i.p) and blood glucose level was determined (at 
time zero) from a small drop of blood collected by tail prick. Rats then received a single 
bolus HHS intraperitoneal injection (50, 200, 400 or 800 mg/ml). The blood glucose 
levels were again monitored by tail prick after 30, 60, 120, 180 and 240 minute post 
injection. 
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3.5 Chronic Studies 
 
3.5.1 Experimental Protocol 
 
 Preparation of Hypoxis hemerocallidea Tea (HHT) 3.5.1.1
 
Freshly boiled tap water was added to HH corm (3.81g/500 ml) for 5 minutes. 
Thereafter, it was filtered through a cheese cloth and Whatman filter paper (no 4 and 1 
respectively) using a vacuum system. The HHT was allowed to cool at room 
temperature and given in drink water. Fresh tea was prepared every second day. 
 
 Preparation of the high-fat diet (HFD) 3.5.1.2
 
The high-fat diet (HFD) was prepared in-house  and contained the ingredients stipulated 
in Table 3.1. 
 
Table ‎3.1. The compositions of the diet prepared in-house 
 
 
 
 
 
 
 
 
 
 
 
 
Content Quantity (g) 
 
Cooking fat 400 
Fructose 100 
Casein 100 
Cholesterol 10 
Rat pellets (Chow) 390 
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 Treatment Protocol 3.5.1.3
 
The rats were randomly divided into 6 different groups, with six rats assigned to each 
group (n=6) and each group housed in separate cages. Each group received the 
following treatment ad libitum. 
Group (1), control group: the rats in this group were feed normal laboratory pellets.  
Group (2), the high-fat diet group (HFD): the rats in this group were given the HFD.  
Group (3), the diabetes group (DM): the rats in this group were injected with STZ 
(40mg/kg) and fed the HFD for 7 weeks.  
Group (4), the Diabetes with Hypoxis hemerocallidea treatment (DM-HH group): 
diabetes was induced by STZ injection (40mg/kg) in rats. The rats were then fed 
the HFD and treated with HH (800mg/kg) for 7 weeks. 
Group (5), the Hypoxis hemerocallidea pre-treatment group (HHPT): rats were 
given HH and fed the HFD for 3 weeks. Diabetes was then induced by STZ 
(40mg/ml). Rats continued on the HFD and HH treatment another 4 weeks. 
Group (6), the Hypoxis Hemerocallidea group (HH): started with treatment of HHT 
and fed normal laboratory pellets for 7 weeks. Figure 3.1 shows the diagram 
illustrating treatment protocols in chronic study. 
 
The body weight of the rats were measured weekly for 7 weeks. Average intake water 
by the rats in each group was also measured. The data was used to calculate the HH 
concentration needed in the drinking water. An intraperitoneal glucose tolerance test 
(IPGTT) was performed at the end of week 6. After being on the high fat diet for 7 
weeks, the animals fasted overnight. The next day the rats were anesthetized and 
dissected. 
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Figure 3.1. The diagram illustrating treatment protocols in chronic study. 
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 Blood Collection 3.5.1.4
 
At the end of treatment, rats were anesthetized by sodium pentobarbital and killed by 
exsanguination. Blood samples were collected and allowed to clot for 30 minutes. A 
clear serum was separated by centrifuge (3000 x g, 15 minutes) and stored at -20 °C for 
further use and for the determination of insulin and fatty acids. 
 
 
 Parameters Assessed 3.5.1.5
 
 Intraperitoneal Glucose Tolerance Test (IPGTT) 3.5.1.5.1
 
At the end of 6 weeks of treatment, an IPGTT tests were performed on all the rats using 
a handheld Contour TS blood glucose meter. After an overnight fast, the rats were 
anaesthetized with sodium pentobarbital (50 mg/kg i.p) and time zero fasting blood 
glucose level determined from a drop of blood collected by snipping the tail. The Rats 
were then injected with 1.5 g/kg glucose and the blood glucose levels were monitored at 
10, 30, 60, and 120 minutes post injection. 
 
 Tissue Histology 3.5.1.5.2
 
After the 7 week treatment, the rats were dissected. Liver, adipose tissue and pancreas 
was removed for histological evaluation. These organs were fixed in 10% neutral 
buffered formalin solution for about 7 days. 
 
The 10% neutral buffered formalin solution was prepared in the following way; 
Formaldehyde 37% (100 mL), distilled water (900 mL), anhydrous monobasic sodium 
phosphate (NaH2PO4) (4.0 g) and disodium hydrogen phosphate (Na2HPO4) (6.5 g). 
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After fixation, the tissues were cut into small sections and placed in properly labelled 
cassettes. The tissues sample were then dehydrated through a series of graded ethanol 
solutions and cleared in xylene. Table 3.2 below shows time cycle of processing tissues. 
 Table ‎3.2. Time cycle of processing tissues. 
Steps Solutions  
 
Time (hour) 
1 70% ethanol 2 
2 80% ethanol 2 
3 90% ethanol 2 
4 100% ethanol 2 
5 100% ethanol 2 
6 Xylene 1 2 
7 Xylene 2 2 
8 Wax bath 1 2 
9 Wax bath 2 2 
 
At the end of the 18 hour cycle, the tissues were embedded in paraffin wax and cut into 
sections of 6 µm. Each section was then placed on a staining rack and put into a hot air 
oven at 60°C for approximately 30 minutes to further fix the tissues. 
 
After that, the wax was melted and the section were stained with haematoxylin (1g 
haematoxylin, 50g potassium alum, 0.2 g sodium iodate, 1 L dH20, 50g choral hydrate 
and 1g citric acid) and eosin (1% eosin, 1% phloxine and distilled water (2:1:3)), as 
shown in Table 3.3 below. 
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                       Table ‎3.3. Procedure for Haematoxylin and Eosin Stain. 
 
Steps Solutions Time (minutes) 
 
1 Xylene (x2) 5 each 
2 100% ethanol (x2) 5 each 
3 90% ethanol 5 
4 80% ethanol 5 
5 Haematoxylin 15 
6 Rinsed in tap water 1 
7 Scott‘s tap water 2 
8 1% acid alcohol 2 
9 Eosin 1 
10 Rinsed in tap water 1 
11 80% ethanol= 2 
12 90% ethanol 2 
13 100% ethanol 2 
14 Xylene (x2) 2each 
 
 Determination of insulin 3.5.1.5.3
 
Insulin was measured in the plasma using a commercially available )Human Insulin 
ELISA -Enzyme-Linked Immunosorbent Assay, Abcam USA) kit. This assay employs 
an antibody specific for Human Insulin coated on a 96-well plate. A volume of 100 µl 
of Standard (0 μUI/ml – 300 μUI/ml) and 10 µl serum samples were pipetted into the 
wells and insulin present in a sample is bound to the wells by the immobilized antibody. 
The wells were washed 4 times with wash solution and 100 µl biotinylated anti-human 
insulin antibody (HRP) was added. After washing away unbound biotinylated antibody, 
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HRP-conjugated streptavidin was pipetted to the wells. The wells were washed again. 
100 µl a TMB substrate solution was added to the wells and colour develops in 
proportion to the amount of insulin bound. A volume of 50 µl of stop solution was 
added to change the colour from blue to yellow, and the intensity of the colour is 
measured at 450 nm. Insulin content was determined by an ELISA. 
 
 Determination of free fatty acid (FFA) 3.5.1.5.4
 
Fatty acid was measured in the serum using a commercially available (Free Fatty 
Acid Quantification Kit Biovision USA). This assay employs fatty acid coated on 
a 96-well plate. 50 µl Standards and 50 µl serum samples were pipetted into the 
wells. The wells were added 2 µl ACR regent was added to each well and plant 
were incubated at 37°C for 30 minutes. 50 µl reaction mix was added plates 
incubated at   37°C for 30 minutes and the intensity of the colour was measured at 
570 nm. FFA content was determined by an ELISA. 
 
 Determination of insulin resistance (IR) and the‎β-cell‎function‎(%β) 3.5.1.5.5
 
The insulin resistance and the β-cell function were determined using the Homeostatic 
model assessment (HOMA). The insulin resistance and β-cell function can be estimated 
from fasting glucose and insulin levels. The approximating equation for insulin 
resistance in the early model used a fasting plasma sample, and was derived by use of 
the insulin-glucose product, divided by a constant (Wallace et al., 2004; Yin et al., 
2009). 
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3.6 Insulin secretion Studies 
 
3.6.1  Preparation of Hypoxis hemerocallidea solution (HHS) 
 
The phenol red free RPMI- 1640 medium was added to HH corm (2.38g/100 ml) to get 
low HH concentrations (100 µg/ml) and (5.95g/100 ml) to get high HH concentrations 
(500µg/ml). Thereafter, it was filtered through a 0.22µm syringe filter. 
 
3.6.2 Isolation of rat pancreatic islets 
 
The isolation of islets was conducted by using the collagenase digestion method 
modified in the laboratory at the University of Stellenbosch. The pancreas was removed 
and placed in a siliconized vial containing 2 ml of collagenase solution. Digestion was 
performed at 37°C for 20 minutes. Subsequently, the digestion was stopped by the 
addition of cold HBSS and the suspension was washed twice with HBSS. Islet 
separation was done by centrifugation on the histopaque discontinuous gradient 
(HBSS/1.083 g/ml, 16 minutes, 800 x g, and 4 °C). To ensure 100% purity of the 
preparation, islets were handpicked and counted under an inverted microscope. The 
islets were cultured in petri dishes containing phenol free RPMI- 1640 medium 
supplemented with 0.5mM- glucose,  340 µl L-glutamine and 5% fetal calf serum. at 37 
°C in a humidified 5 % CO2 incubator.. 
 
3.6.3 Experimental protocol 
 
Islets were collected and washed twice with PBS. Ten pancreatic islets was had 
suspended three times for 60 min in 2 ml RPMI-1640 solution supplemented with 10 % 
fetal calf serum and 3mM-glucose, after that the entire medium was discarded. 
 
In preliminary studies, the Islets were divided into 2 groups which were incubated on 
low glucose RPMI-1640 medium supplemented with low glucose (3mM) or high 
glucose (20mM). After 60 minute incubation period 1ml of the medium was removed 
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for insulin determination. After a further 60 minutes the incubation medium was again 
removed for determination of insulin. The purpose of the preliminary study was to 
determine whether insulin secretion was the same in the first and second 60 minutes 
incubation period. 
 
 In the main study, the Islets were divided into 4 different groups. Group (1), islets were 
incubated in 2ml RPMI-1640 medium supplemented with 3mM glucose, control group. 
Group (2), islets were incubated in 2ml RPMI-1640 medium supplemented with 3mM 
glucose + 100mg/ml, low HH. Group (3), islets were incubated in 2ml RPMI-1640 
medium supplemented with 3mM glucose + 500mg/ml, high HH. Group (4), islets were 
incubated in 2ml RPMI-1640 medium supplemented with 3mM glucose + 10mg/ml 
glibenclamide. 
 
Islets were incubated for 60 minutes at 37°C. One ml of the incubation medium was 
removed from each group and stored for insulin determination. One ml medium 
supplemented with glucose, to adjust the glucose concentration in each well to 20 ml 
was added to each well. After further 60 minute incubation, the medium was removed 
from the wells for insulin determination. Protein content of islets was determined.  
 
3.6.4 Parameters Assessed 
 
 Determination of insulin level 3.6.4.1
 
Insulin levels in the supernatant was measured in the culture supernatant using a 
commercially available (ab100578 Human Insulin ELISA -Enzyme-Linked 
Immunosorbent Assay, Abcam USA) kit as described under 3.5.1.5.3. 
 
 Determination protein concentration 3.6.4.2
 
A volume of 25 µl of each protein standard (25 µg/ml – 2000 µg/ml) added to the wells 
of a 96 well plate after that the samples were prepared and added to the wells of a 96 
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well plate. The working reagent (WR) was prepared by mixing 5 ml of Reagent A (500 
ml containing /7, sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.1 M 
sodium hydroxide) and 100 µl of reagent B (25 ml containing 4 % cupric sulphate), then 
200 µl of WR per well was added per well. The plate was covered and placed in an 
incubator for 30 minutes at 53 
o
C.  Subsequently the absorbance was read at 560 nm in a 
96 well plate reader. Each sample was analysed in triplicate.  
 
3.7 Data analysis 
All data are reported as means and SEM or median and interquatile range (IQR). 
Statistical differences among groups were analysed by analyses of variance (ANOVA). 
P< 0.05 was considered significantly different. Data analysis was done using GraphPad 
Prism version 5.1 for Windows (GraphPad Software, San Diego, CA, USA). 
 
3.8 Ethical considerations 
 
All experimental procedures were conducted after ethical clearance was obtained from 
the University of the Western Cape Senate Research Committee. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
44 
 
CHAPTER IV 
 
4 Results 
 
4.1 Acute Studies 
 
We determined the effects of a single bolus administration of HH on blood glucose 
level in normal and diabetic rats, after 12 hours fast. Diabetes was induced in the group 
of diabetic rats by intraperitoneal injection of STZ (65 mg/kg). HH was tested at four 
different concentrations, i.e. 50, 200, 400 and 800 mg/kg. 
 
4.1.1 Normal rats 
 
The results are shown in Figure 4.1 and in Table 4.1. 50 mg/kg HH did not decrease the 
blood glucose level significantly over the 240 minute period. HH at a concentration of 
200 mg/kg or 400 mg/kg decreased blood glucose level at 60 minutes and 120 minutes 
respectively (P ≤ 0.05, P ≤ 0.01, P ≤ 0.001), and the blood glucose level remained below 
the time zero value (Table 4.1) for the rest of the 240 minutes duration. 
 
HH at a dose of 800 mg/kg decreased blood glucose the fastest. It was significantly 
lower after 30 minutes, and remained significantly below the time zero value (P ≤ 0.05, 
P ≤ 0.01, P ≤ 0.001), (Table 4.1) for the rest of the 240 minutes duration. 
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              Figure ‎4.1. Effect of HH on blood glucose levels in normal rats. 
                 Data is shown as mean ± SD of 7 animals per group. The statistics is given in Table 4.1 
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Table ‎4.1. Effect of HH on blood glucose levels in normal rats.  
 
 
Values are expressed as the mean ± SD. N = 7 rats.  
At each dose of HH blood glucose level were compared to zero min using ANOVA (*P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001). 
HH concentration            
injected 
Time 
  
 
0min 
 
 
30min 
 
 
60min 
 
 
120min 
 
 
180min 
 
 
240min 
 
50mg/kg 
Blood Glucose (mmol/L) 5.4±0.5 5.3±0.6 5±0.6 5±0.9 5±1.3 5.2±1.3 
P(Comparison vs 0 min)  > 0.05 > 0.05 > 0.05 > 0.05 > 0.05 
 
200mg/kg 
Blood Glucose (mmol/L) 5.4±0.4 5.1±0.5 4.8±0.5
**
 4.4±0.5
***
 4.4±0.6
***
 4±0.4
***
 
P(Comparison vs 0 min)  > 0.05 < 0.01 < 0.001 < 0.001 < 0.001 
400mg/kg Blood Glucose (mmol/L) 4.9±0.6 4.7±0.6 4.4±0.7 4.3±0.8
*
 4.1±0.6
**
 4±0.8
***
 
P(Comparison vs 0 min)  > 0.05 > 0.05 < 0.05 < 0.01 < 0.001 
800mg/kg Blood Glucose (mmol/L) 5±0.6 3.9±1.1
*
 3.6±1.3
**
 3.6±1.0
***
 3.8±1.2
**
 3.4±1.1
***
 
P(Comparison vs 0 min)  < 0.05 < 0.01 < 0.001 < 0.01 < 0.001 
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4.1.2 Diabetic rats: 
 
The results for diabetic rats are shown in Figure 4.2 and in Table 4.2. 50 mg/kg HH 
decreased blood glucose level between 120 minutes and 180 minutes (P ≤ 0.01, P ≤ 
0.001). HH at a concentration of 200 mg/kg or 400 mg/kg decreased blood glucose 
levels between 60 minutes and 180 minutes. The values of blood glucose level at 240 
minutes were not significant from time zero (P> 0.05). 
 
HH at a dose of 800 mg/kg decreased blood glucose the fastest and was significantly 
lower after 60 minutes (P ≤ 0.001). The blood glucose level remained significantly 
below the time zero value (Table 4.2) until 240 minutes. 
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Figure ‎4.2. Effect of HH on blood glucose levels in diabetic rats. 
Data is shown as mean ± SD of 7 animals per group. The statistics is given in Table 4.2.
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Table ‎4.2. Effect of HH on blood glucose levels in DM rats 
Values are expressed as the mean ± SD. N = 7 rats.  
At each dose of HH blood glucose level were compared to zero min using ANOVA (*P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001). 
 
HH concentration 
injected 
 
Time  0min 30min 60min 120min 180min 240min 
 
50mg/kg 
Blood Glucose (mmol/L) 30.3±2.2 30.6±2.0 29.4±2.4 28.7±2.2
**
 28.7±2.7
**
 29.2±2.6 
P(Comparison vs 0 min)  > 0.05 > 0.05 < 0.01 < 0.01 > 0.05 
 
200mg/kg 
Blood Glucose (mmol/L) 31±2.3 28.8±3.7 26.1±4.8
**
 24.7±4.9
***
 25±4.1
***
 27.3±5.5 
P (Comparison vs 0 min)  > 0.05 < 0.01 < 0.001 < 0.001 > 0.05 
 
400mg/kg 
Blood Glucose (mmol/L) 32.1±2.7 31.2±2.4 28.4±2.7
***
 28±2.5
***
 29.1±1.9
**
 31.7±2.1 
P(Comparison vs 0 min)  > 0.05 < 0.001 < 0.001 < 0.01 > 0.05 
 
800mg/kg 
Blood Glucose (mmol/L) 31.3±2.9 29.6±2.4 24.4±3.3
***
 23.8±2.4
***
 24.3±2.5
***
 24.6±2.7
***
 
P(Comparison vs 0 min)  > 0.05 < 0.001 < 0.001 < 0.001 < 0.001 
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4.2 Chronic Studies 
 
4.2.1 Body weight gain 
 
The initial mean body weights of the six groups of animals were not significantly 
different before the dietary intervention as shown in Table 4.3. 
 
Animals in the control group, HFD group and HH group statistically increased in 
weight over the seven week period. The weekly weight gain in the HFD group and the 
HH group were not significantly different from the control group. The total weight gain 
in the DM group (P ≤ 0.001), the DM-HH group P ≤ 0.01)  and the DM-HHPT group P 
≤ 0.01)  were significantly lower than the control group as shown in Table  4.3.The total 
weight gain in the DM-HH group and the DM-HHPT group were significantly higher 
than the DM group (P ≤ 0.001). 
 
Animals in the DM group gained weight the first two weeks, but thereafter began to 
lose weight. At the end of seven weeks the animals gained significantly less weight than 
the rest (Table 4.3). 
 
Animals fed a HFD have more visceral fat compared to the control group, as shown in 
Figure 4.4. 
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Figure ‎4.3. Weekly weight gain for the period of treatment in rats.  
Values are the mean ± SD of 6 animals per group. Abbreviations: C, control; HFD, High-Fat Diet; DM, 
Diabetes Mellitus; DM-HH Diabetes Mellitus-Hypoxis hemerocallidea; DM-HHPT, Diabetes Mellitus- 
Hypoxis hemerocallidea pre-treatment; HH, Hypoxis hemerocallidea. Statistics are indicated in Table 
4.3. 
 
 
Figure ‎4.4. Visceral fat in rats from the control or diabetic groups.  
(A) Normal rats (B) HFD rats. 
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Table ‎4.3. Weekly weight gain for the period of treatment in rats. 
 
Weeks  Groups Control HFD DM DM-HH DM-HHPT HH 
0 weeks 256±25 255±20 258±13 249±15 240±16 259±9 
P (Comparison to 
Control) 
 > 0.05 > 0.05 > 0.05 > 0.05 > 0.05 
7 weeks 329±30 349±38 285±36 302±58 296±42 552±15 
P (Comparison to 
Control) 
 > 0.05 > 0.05 > 0.05 > 0.05 > 0.05 
Body weight gain 73± 11 95± 20 27± 32*** 53± 35**
,#
 
      
56± 30**
,#
 92± 10 
P (Comparison to 
Control) 
 > 0.05 <  0.001 <  0.001 < 0.001 > 0.05 
Values are expressed as the mean ± SD. N = 6 rats. Weight (g). Significant differences between the treated and the control groups (ANOVA) are indicated *P ≤ 0.05; 
**P ≤ 0.01; ***P ≤ 0.001 compared to control group, # P ≤ 0.05 compared to DM group. 
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4.2.2 Intraperitoneal Glucose Tolerance Test (IPGTT) 
 
The results of the IPGTT performed at week 6 are shown in Figure 4.5 and Table 4.4. 
At time zero the blood glucose level of the HFD group (5.8±0.5mmol/l) and the HH 
group (4.9±0.7mmol/l) were in the normal range, and were not significantly different (P 
> 0.05) from the control group (5.0±0.2mmol/l). The blood glucose level of all the 
diabetic groups were significantly higher (DM group 19.3±3.3mmol/l, DM-HH group 
11.0±3.6 mmol/l and DM-HHPT group 17.9±1.9 mmol/l) compared to the control group 
(P ≤ 0.001). The blood glucose levels in the DM-HHPT group were not significantly 
different from the DM group and the blood glucose level in DM-HH group were 
significantly lower than the DM group (P ≤ 0.001). 
 
After glucose load peak blood glucose levels were measured after 30 minutes in the 
control group (9.0±0.6mmol/l), the HFD group (9.8±0.4 mmol/l), the DM-HH group 
(21±5.7 mmol/l) and the DM-HHPT group (27.8±5.3 mmol/l). In the HH group the 
blood glucose level reached a peak at 60 minutes (7.6±0.6 mmol/l). In the DM group 
two peaks were recorded one after 10 minutes (27.2±7.1mmol/l) and another after 60 
minutes (31±5.2 mmol/l). 
 
In the control, HFD, DM-HH, DM-HHPT and HH groups the blood glucose level after 
120 minutes were not significantly different from the time zero value. The blood 
glucose level after 120 minutes in the DM group (P ≤ 0.01) was significantly higher 
than from the time zero value 
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Figure ‎4.5. Intraperitoneal glucose tolerance tests (IPGTT) performed at week 6. 
Values are the mean ± SD of 6 animals per groupAbbreviations: C, control; HFD, High-Fat Diet; DM, 
Diabetes Mellitus; DM-HH Diabetes Mellitus-Hypoxis hemerocallidea; DM-HHPT, Diabetes Mellitus- 
Hypoxis hemerocallidea pre-treatment; HH, Hypoxis hemerocallidea. The statistics are given in Table 
4.4. 
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Table ‎4.4. Intraperitoneal glucose tolerance tests (IPGTT) performed at week 6 
 
Time     Groups          Control HFD DM DM-HH DM-HHPT HH 
0 min 5.0±0.2 5.8±0.5 19.3±3.3 11.0±3.6 17.9±1.9 4.9±0.7 
10 min 6.4±0.5 7.4±0.8 27.2±7.1 16.7±8.2 23.7±3.9 5.1±0.7 
30min 9.0±0.6 9.8±0.4 26.0±6.7 21.1±5.7 27.8±5.3 7.4±0.6 
60 min 8.9±0.5 9.7±0.4 31.0±5.2 16.9±5.0 22.3±5.0 7.6±0.6 
120 min 5.5±0.4 6.4±0.7 28.2±7.1
#
 15.9±3.8 21.2±4.0 5.6±0.5 
Area under the curve of the IPGTT        
 29.24±1.9 32.47±1.8 108.5±4.4*** 73.06±3.3*** 96.11±4.1*** 26.01±1.3 
P (Comparison to Control)  > 0.05 < 0.001 < 0.001 < 0.001 > 0.05 
Values are expressed as the mean ± SD. N = 6 rats per group. Blood Glucose (mmol/L).  
Significant differences between the treated and the control groups (ANOVA) are indicated ***P ≤ 0.00.  #P ≤ 0.01 compared between 0 min and 120 min
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4.2.3 Serum free fatty acids (FFA) in the rats on the different dietary regimes 
 
Figure 4.6 shows the serum free fatty acid levels after seven weeks on the respective diets. 
Statistically the FFA in the HH group (0.23±0.03 mmol/l; P > 0.05) was not significantly 
different from the control group (0.23±0.04 mmol/l). The FFA in the HFD group 
(0.37±0.05 mmol/l; P ≤ 0.001), the DM group (0.47±0.05 mmol/l; P ≤ 0.001), the DM-HH 
(0.39±0.06 mmol/l; P ≤ 0.001) group and the DM-HHPT group (0.32±0.07 mmol/l; P ≤ 
0.01) were significantly higher than the control group. The FFA in the DM-HH group (P ≤ 
0.01) and the DM-HHPT group (P ≤ 0.001) were significantly lower than the DM group. 
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Figure ‎4.6. Serum free fatty acids in the rats on the different dietary regimes. 
Values are the mean ± SD of 6 animals per group.Abbreviations: C, control; HFD, High-Fat Diet; 
DM, Diabetes Mellitus; DM-HH Diabetes Mellitus-Hypoxis hemerocallidea; DM-HHPT, Diabetes 
Mellitus- Hypoxis hemerocallidea pre-treatment; HH, Hypoxis hemerocallidea. Significant 
differences between the treated and the control groups (ANOVA) are indicated ** P ≤ 0.01, *** P ≤ 
0.001. 
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4.2.4 Serum insulin levels in the rats on the different dietary regimes 
 
 Figure 4.7 shows the serum insulin levels after seven weeks on the respective diets. 
Statistically the serum insulin level in the HH group (8.2 ± 0.48 μUI/ml protein; P > 0.05) 
was not significantly different from the control group (7.7 ± 0.77 μUI/ml protein). The 
serum insulin levels in the HFD group (6.2 ± 0.76 μUI/ml protein; P ≤ 0.05 ), the DM 
group (2.0 ± 0.9 μUI/ml protein; P ≤ 0.001), the DM-HH group (3.4 ± 0.7 μUI/ml protein; 
P ≤ 0.001) and the DM-HHPT group (3.0 ± 1.1 μUI/ml protein; P ≤ 0.001) were 
significantly lower than the control group. The DM-HH group (P ≤ 0.05) were significantly 
higher than the DM group and the DM-HHPT group was not significantly different from 
the DM group. 
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Figure ‎4.7. Serum insulin levels in the rats on the different dietary regimes. 
Values are the mean ± SD of 6 animals per group.Abbreviations: C, control; HFD, High-Fat 
Diet; DM, Diabetes Mellitus; DM-HH Diabetes Mellitus-Hypoxis hemerocallidea; DM-
HHPT, Diabetes Mellitus- Hypoxis hemerocallidea pre-treatment; HH, Hypoxis 
hemerocallidea. Significant differences between the treated and the control groups 
(ANOVA) are indicated * P ≤ 0.05, *** P ≤ 0.001. 
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4.2.5 β-cell‎function‎(β)‎in‎the‎rats‎on‎the‎different‎dietary‎regimes 
 
Figure 4.8 shows the β-cell function after seven weeks on the respective diets. Statistically 
the β-cell function in the HH group (98 ± 9 %; P > 0.05) was not significantly different 
from the control group (117 ± 27 %). The β-cell function in the HFD group (62 ± 8 %; P ≤ 
0.001), the DM group (3 ± 1 %; P ≤ 0.001), the DM-HH (11 ± 9 %; P ≤ 0.001) group and 
the DM-HHPT group (4 ± 2 %; P ≤ 0.001) were significantly lower than the control 
group.The β-cell function in the DM-HH group and the DM-HHPT group were not 
significantly different from the DM group. 
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Figure ‎4.8. β-cell function in the rats on the different dietary regimes. 
Values are the mean ± SD of 6 animals per group.Abbreviations: C, control; HFD, High-Fat Diet; DM, 
Diabetes Mellitus; DM-HH Diabetes Mellitus-Hypoxis hemerocallidea; DM-HHPT, Diabetes Mellitus- 
Hypoxis hemerocallidea pre-treatment; HH, Hypoxis hemerocallidea. Significant differences between 
the treated and the control groups (ANOVA) are indicated *** P ≤ 0.001. 
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4.2.6 Insulin resistance (IR) in the rats on the different dietary regimes 
 
Figure 4.9 shows the Insulin resistance (IR) levels after seven weeks on the respective diets. 
Statistically the IR level varied between (2.42 ± 0.29 IR) in the HFD group and (3.59 ± 1.5 
IR) in the DM-HHPT group. No significantly different was found between any of the 
groups (P > 0.05). 
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Figure ‎4.9. Insulin resistance (IR) in the rats on the different dietary regimes 
Values are the mean ± SD of 6 animals per group.Abbreviations: C, control; HFD, High-Fat Diet; 
DM, Diabetes Mellitus; DM-HH Diabetes Mellitus-Hypoxis hemerocallidea; DM-HHPT, Diabetes 
Mellitus- Hypoxis hemerocallidea pre-treatment; HH, Hypoxis hemerocallidea. Significant differences 
between the treated and the control groups (ANOVA). 
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4.2.7 Morphology of liver and pancreas after 7 weeks on different dietary regimes 
 
 Liver 4.2.7.1
 
Figure 4.10 shows the gross appearance of the liver in the control rats and in the rats 
exposed to HFD. There was a marked enlargement of the liver in the HFD rats (Figure 4.10 
B) compared to the liver in the control rats which exhibited a normal liver size and colour 
(Figure 4.10 A). Meanwhile, the beige colour observed in the liver of HFD rats is a gross 
characteristic feature of a fatty liver. The histological observation of the liver in rats after 7 
weeks on different dietary regimes showed some morphological changes within the liver 
parenchyma of some rats. In the control rats the hepatocytes, the portal triads and the 
microvasculature appeared within normal limit (Figure 4.11 A). Similarly, the liver of the 
HH treated rats did not reveal any pathological alterations (Figures 4.11 F). However, there 
were obvious distortions in the architecture of the liver parenchyma of the rats that received 
an STZ injection (DM, DM-HH, DM-HHPT groups); the livers in these groups were 
presented with a dilatation of the sinusoids in the liver parenchyma, a dislocation of the 
wall of the central vein, a growing numbers of necrotic cells and lipid accumulation within 
the hepatocytes Figures 4.11 C, D, E). These observations were similar to what was 
observed in the liver of the rats exposed to HFD (Figures 4. 11 B).  
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Figure ‎4.10. Gross appearance of the liver in Normal (A) and 7–week HFD (B) rats. 
. 
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Figure ‎4.11. H&E staining showing morphology of the rat liver exposed to Hypoxis 
hemerocallidea (HH) for 7 weeks. 
(A) control, (B ) HFD,  (C) DM,  (D) DM-HH,  (E) DM-HHPT and  (F) HH;  Cv  central vein; LA 
lipid accumulation; NC necrotic cells; LC Lymphocytic cell; Bar = 20 μm.400X . 
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 Pancreas 4.2.7.2
 
The histological observation of the pancreas in rats after 7 weeks on different dietary 
regimes is presented in Figure 4.12. The pancreatic tissues in the normal and HH-treated 
rats appeared normal with prominent and healthy islets of Langerhans (Figures 4.12 A, F); 
while there were high numbers of lymphocytic infiltrations observed in the other groups 
(Figures 4.12 B, C, D and E). The sizes of the islets of Langerhans were relatively reduced 
in the pancreas of rats treated with STZ with a massive distortion on their cellular 
architectures. This observation characterized the histological appearance of the islet of 
langerhans seen in the HFD rats. The Islets of langerhans in both the control and the HH 
groups were not affected 
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Figure ‎4.12. H&E staining showing morphology of the rat Pancreas exposed to Hypoxis 
hemerocallidea (HH) for 7 weeks. 
(A) control, (B ) HFD,  (C) DM,  (D) DM-HH,  (E) DM-HHPT and (F) HH; BV blood vessel; Ex  
exocrine portion of pancreas; IL  islets of Langerhans; Bar = 10 μm.400X. 
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4.3 Insulin secretion studies 
 
Preliminary studies indicated that insulin secretion in low (3 mM) or high (20mM) glucose 
remained constant over the 120 minutes experimental period (Figure 4.13). 
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Figure ‎4.13. Preliminary studies for insulin Secretion in Isolated rat Islets. 
Values are the mean ± SD of 10 islets per group. Abbreviations: low G= low glucose, high G= high glucose 
 
 
Figure 4.14 shows insulin secretion by pancreatic islet cells. Statistically the insulin 
secretion in high glucose group (1.5 ± 0.17 mIU/mg protein; P ≤ 0.01) was significantly 
higher than the low glucose group (1.10 ± 0.13 mIU/mg protein). Also, the insulin secretion 
in high glucose + low HH group (1.94 ± 0.11 mIU/mg protein; P ≤ 0.01) was significantly 
higher than the low glucose + low HH group (1.5 ± 0.11 mIU/mg protein) and the insulin 
secretion in high glucose + glibenclamide 10 mg/ml group (2.3 ± 0.15 mIU/mg protein; P ≤ 
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0.001) was significantly higher than the low glucose + glibenclamide 10 mg/ml group (1.75 
± 0.16 mIU/mg protein). The insulin secretion in high glucose + high HH  (2.35 ± 0.14 
mIU/mg protein; P > 0.05) was not significantly different from the low glucose + high HH 
group (2.34 ± 0.24 mIU/mg protein). 
L
o
w
 G
H
ig
h
 G
L
o
w
 G
 +
 L
o
w
 H
H
H
ig
h
 G
+
 L
o
w
 H
H
L
o
w
 G
 +
H
ig
h
 H
H
H
ig
h
 G
 +
 H
ig
h
 H
H
L
o
w
 G
 +
 G
B
H
ig
h
 G
+
 G
B
0
1
2
3
* *
* * *
* *
I
n
s
u
li
n
 S
e
c
r
e
t
io
n
(
m
I
U
/m
g
 p
r
o
t
e
in
)
 
Figure ‎4.14. Insulin Secretion in Isolated rat Islets. 
Values are the mean ± SD of 10 islets per group. Abbreviations: low G low glucose, high G high glucose, low 
HH low Hypoxis hemerocallidea; high HH high Hypoxis hemerocallidea; GB glibenclamide. Significant 
differences are indicated. ** P ≤ 0.01, *** P ≤ 0.001. 
 
 
 
Figure 4.15 shows the effect of HH on insulin secretion at a low glucose concentration. 
Statistically the insulin secretion in low glucose + low HH group (1.5 ± 0.11 mIU/mg 
protein; P ≤ 0.01), low glucose + high HH (2.34 ± 0.24 mIU/mg protein; P ≤ 0.001) and 
low glucose + glibenclamide 10 mg/ml (1.75 ± 0.16 mIU/mg protein; P ≤ 0.001) were 
significantly higher than the  low glucose group (1.10 ± 0.13 mIU/mg protein). The insulin 
secretion in low glucose+high HH (P ≤ 0.001) was significantly higher than low glucose+ 
low HH group. 
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Figure ‎4.15. The Insulin Secretion at a low glucose concentration. 
Values represented are the mean ± SD of 10 islets per group. Abbreviations: low G low glucose, low HH low 
Hypoxis hemerocallidea; high HH high Hypoxis hemerocallidea; GB glibenclamide. Significant differences 
(ANOVA) are indicated ** P ≤ 0.01, *** P ≤ 0.001. 
 
Figure 4.16 shows the effect of HH on insulin secretion at a high glucose concentration. 
Statistically the insulin secretion in high glucose + low HH group (1.94 ± 0.11 mIU/mg 
protein; P ≤ 0.001), high glucose + high HH (2.35 ± 0.17 mIU/mg protein; P ≤ 0.001) and 
high glucose + glibenclamide 10 mg/ml (2.3 ± 0.15 mIU/mg protein; P ≤ 0.001) were 
significantly higher than the high glucose group (1.5 ± 0.17 mIU/mg protein). The insulin 
secretion in high glucose + high HH (P ≤ 0.001) was significantly higher than high glucose 
+ low HH group. 
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Figure ‎4.16. The insulin secretion at a high glucose concentration. 
Values are the mean ± SD of 10 islets per group. Abbreviations: G; glucose, HH; Hypoxis hemerocallidea; 
GB glibenclamide. Significant differences are indicated *** P ≤ 0.001. 
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CHAPTER V 
 
5 Discussion 
 
Diabetes mellitus is a metabolic disease that can result in chronic-hyperglycaemia due to an 
imbalance in the metabolism of carbohydrate, fat and protein which may result in an 
impaired secretion of insulin (Kitabchi et al., 2001; Drouin et al., 2009; Alsahli & Gerich, 
2010).  T1DM is caused by an autoimmune assault to the β-cells while the pathogenesis of 
T2DM is variable, whereby the degree of damage to the cells is relative to the varying 
degree of insulin resistance (Guidelines & Force, 2005; Donath & Shoelson, 2011; 
Atkinson et al.,2014). The main aim of this research was to study the possible effect of HH 
on blood glucose levels in rats with type 2 diabetes.  The study was based on three parts 
acute, chronic and insulin secretion.  
 
5.1  Acute Studies 
 
This study has shown that HH had the ability to decrease blood glucose level in STZ 
induced diabetic rats. In normal rats (Figure 4.1), HH at concentrations of 200 mg/kg or 
400 mg/ kg decrease the blood glucose level at 60 minutes and 120 minutes, while, HH at a 
concentration of 800 mg/ml HH, decrease the blood glucose level at a faster rate and 
significance was achieved after 30 minutes. In diabetic rats (Figure 4.2), the decrease in 
blood glucose level at concentrations of 200 mg/ kg or 400 mg/kg was observed between 
60 minutes and 180 minutes, while at the high dose of 800 mg/kg the blood glucose level 
decreased at a faster rate and was significant after 60 minutes. HH at a dose of 800 mg/ml 
appears to be the most effective dose to reduce blood glucose level in diabetic rats when 
using the HH as solution (HHS), this is similar to what was reported by Mahomed & 
Ojewole (2003) to be the most effective dose in the study. However, the low dose of 100 
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mg/ kg of HH has been shown to have significant antidiabetic effects in both 
normoglycaemic and hyperglycaemic rats (Erlwanger & Cooper, 2008).  
 
The  antidiabetic properties of HH is probably due to its antioxidant properties (Katerere & 
Eloff, 2008). It appears that the combined effects of hypoxidae, together with other 
constituents like stigmasterols help combat the oxidative stress generated by chloroquine  
(Panda et al., 2009). Both aqueous and ethanolic extracts of  HH are able to scavenge 
hydroxyl radicals through their anti-oxidant property by the presence of hypoxidae that is 
converted to rooperol in vivo (Nair, 2006; Street & Prinsloo, 2013).  
 
5.2 Chronic Studies 
  
A low dose of STZ (40 mg/kg) and HFD was used to induce T2DM in the rats. The HFD 
and low dose of STZ simulates natural disease progression and metabolic characteristics 
typical of individuals at increased risk of developing T2DM (Srinivasan et al., 2005). In 
DM rats treated with HH, there was no significant difference in all parameters evaluated 
between DM-HH group and DM-HHPT group (except the glucose tolerance). Furthermore, 
one should however keep in mind that the duration of diabetes was shorter in the DM-
HHPT group than in the DM-HH group. HH did not show significant effects in the non-
diabetic rats on the different parameter evaluated. The body weight, glucose tolerance, 
histological observation of liver and pancreas and FFA levels were the same as those of the 
control group.  
 
Our study demonstrated a small but not significant gain in body weight of normal rats and 
normal rats treated by HH. HFD rats also had increased body wright, which was most likely 
due to normal body growth and ageing during the 7 weeks of the experiment (Figure 4.3). 
On the other hand, the results of the present study showed a significant decrease in body 
weight in diabetic rats compared to control rats. In diabetic rats, a loss in body weight 
occurs because glucose is not available, resulting in excessive breakdown of tissue protein 
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(muscle wasting) (Pareek et al., 2009). Treatment of diabetic rats with HH as reported by 
Musabayane et al. (2005) caused the body weight in diabetic rats to increase and this can be 
attributed to the improvement in insulin secretion and glycemic control (Musabayane et al., 
2005). After seven weeks of HFD feeding the rats, the visceral fat mass was increased. 
Interestingly, blood glucose was within the normal range and insulin resistance was absent. 
These are probably due to the short duration of the experiment and confirm previous results 
obtained in our laboratory. In order to limit the duration of our experiments, we opted to 
induce diabetes by injecting a low dose of STZ. The visceral fat gain occurred in the 
absence of a significant increase in body weight. The lack of significant increased body 
weight under conditions of high-fat feeding for 7 weeks could be due to enhanced activity 
of the sympathetic nervous system (Moan et al., 1995; Reaven et al., 1996). 
 
Prior to HH treatment, the STZ treated rats were randomly divided into two groups (DM 
and DM-HH). The result of the IPGTT performed at week 6 of the experiment is presented 
in (Figure 4.5) and (Table 4.4). We found a markedly lower fasting glucose in HH treated 
diabetic animals compared to untreated DM animals. The DM group presented a higher 
blood glucose level followed by the DM-HHPT group. The DM-HH group showed the 
lowest blood glucose level in diabetic rats.  Hence, these results demonstrated the 
hypoglycaemic activity of HH. Regarding the glucose tolerance test, all diabetic HH treated 
animals had improved glucose tolerance compared to untreated DM rats, and the 120 min 
post glucose load level was closer to baseline levels. Rats in control, HFD and HH groups 
had a good tolerance for blood glucose level, probably due to improved insulin secretion. 
Contrary to our findings, results from a 13-week study (Bates et al., 2007) have shown that 
glucose tolerance in HFD rats did not differ from DM rats. However, our study was 
conducted over a period of 6 week start period, which may explain the observed differences 
regarding glucose tolerance between the two studies.  
 
This study appears to support the concept that FFA levels are elevated in DM rats. The 
results presented in Figure 4.6 showed significant increase in serum FFA levels of DM rats. 
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FFA inhibit insulin stimulated peripheral glucose uptake in a dose-dependent manner in 
controls and in patients with T2DM (Boden, 1997). We found that serum FFA increased in 
DM rats treated with HH compared to normal rats, while FFA decreased in DM rats treated 
with HH compared to untreated DM rats. The result of this study is in agreement with that 
of Storlien et al., (1986) central adipose level elevates plasma FFA, which exacerbates 
insulin resistance. FFA also depresses the activity of pancreatic β-cells, which could result 
in a rapid progression of diabetes (Storlien et al., 1986). FFA might mediate the insulin 
resistance and impaired glucose tolerance associated with central obesity (Bergman & 
Ader, 2000). Insulin resistance is associated with an abnormal lipid profile. In the Insulin 
resistance state the body uses stored fat as metabolic substrate in preference to glucose, 
resulting in dyslipidemia. Enhanced lipid breakdown causes an increase in the plasma free 
fatty acid levels with subsequent changes in lipoprotein composition  (Van Gaal et al., 
2006). 
 
T1DM and T2DM are characterized by β-cell depletion, with a 70–80% loss in β-cell 
function in T1DM and 25–50% in T2DM; although common to both they occur through 
distinctly different mechanisms (Green et al.,  2003; Young et al., 2000). Diabetic 
pancreatic fragments produce about 50% less insulin compared to the normal healthy 
pancreas (Lotfy, 2012). The present study has shown a pronounced reduction in levels of 
serum insulin in untreated diabetic rats compared to normal rats (Figure 4.7).  In diabetic 
rats, the serum insulin levels were decreased because the β-cell is not able to increase its 
insulin secretory response and maintain a state of chronic hyperinsulinemia (Reaven, 1988). 
The changes in insulin secretion would be entirely explained by disorder of β-cell function 
(Kahn et al., 1989). Apoptosis is probably the main form of β-cell death in both forms of 
the disease. It has been suggested that the mechanisms leading to nutrient and cytokine 
induced β-cell death in T2DM and T1DM, respectively (Green et al.,  2003). Treatment of 
diabetic rats with HH showed a significant elevation in serum insulin levels compared to 
diabetic rats. These results suggest the HH may improve insulin levels in serum via 
enhancement of insulin secretion in rats only when the blood glucose level was above the 
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normal range. The increase serum insulin level is accompanied increase in β-cell function 
(Park et al., 2007).  Figure 4.8 showed the β-cell function in HFD rats and DM rats was 
significantly lower than the normal rats. Also, β-cell function was similar between the two 
HH treatment groups and DM group. The HOMA-IR model has become a widely used 
clinical and epidemiological tool and, when used appropriately, it can yield valuable data 
(Wallace et al., 2004). However, as with all models, the primary input data need to be 
robust, and the data need to be interpreted carefully (Lan et al., 2011), The results obtained 
and shown in Figure 4.9 does not support the development of insulin resistance in the DM 
rats. The large standard errors, due to the variation in fatty acid and serum insulin levels 
measured, make it very difficult to make much inference from the data. 
 
The study also investigated the effect of HH on liver and pancreatic function in diabetic and 
HFD rats by histological observation. There was a marked enlargement in the liver with in 
HFD and DM rats (Figure. 4.11. B, C), dilation and congestion of central vein, lipid 
accumulation and hepatic sinusoids were observed in the hepatic sections. The incidence 
and intensity of changes in HH rats was much lower compared with HFD and DM rats 
(Figure. 4.11. D, E). However, the DM rats treated by HH presented with some lipid 
accumulation. On the other hand, the liver of normal rats treated by HH did not show any 
pathological alteration (Figure. 4.11. F). Similar observations were made by Sahin et.al 
(2007) in DM and HFD rats, this study the histopathology of the liver had vacuolated 
eosinophilic cytoplasm with ground-glass appearance and fatty inclusions (Sahin et al., 
2007), the histopathological examination of the livers of control mice revealed severe 
hepatic fat accumulation along with increased liver weight; however, this was accompanied 
with only mild elevation of liver specific enzymes (Mookkan et al., 2014).  
 
The HFD rats and the DM rats presented with high number of Lymphocytic infiltration and 
massive distortion of the pancreatic cellular architecture (Figure. 4.12. B, C), while the 
normal rats treated by HH had a healthy pancreatic morphology similar to that of the 
normal control rats (Figure. 4.12. F). Treatment with HH showed a slight hypertrophy of 
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Langerhans islets in pancreas compared to DM rats (Figure. 4.12. D, E). The relevant 
reduction in the size of the islet cell in DM rats was similar to that observed in the HFD 
rats. The result of this study is in agreement with that of  Yan et al., (2006) who also did 
study the  histological changes in pancreatic DM rats. The histological observation in 
pancreatic diabetic rats treated by M. emarginata showed the β-cells regeneration (Gandhi 
& Sasikumar, 2012). 
Following acute treatment, relatively moderate to high doses of HHT (800 mg/kg) produced 
significant reductions in the blood glucose concentrations normal and DM rats. While it is 
likely that the hypoglycemic effect of the HH is largely due to its phytosterols or sterolin 
content, the exact mechanism of its hypoglycemic action is still obscure and will have to 
await further studies (Mahomed & Ojewole, 2003). The present study reports that the HH 
can have a protective effect against a HFD induced obesity in rats through an enhanced 
expression of uncoupling proteins and elevated phosphorylation in the visceral adipose 
tissue (Pareek et al., 2009). 
 
5.3 Insulin secretion studies 
 
This study also showed the effect of HH on pancreatic islet cell insulin secretion.  When the 
demand for insulin is chronically increased by physiological or pathological changes, beta 
cells can adapt by enhancing insulin secretion via increased beta cell function and/or 
increased beta cell mass  (Unger, 1991; Aronoff et al., 2004). Inadequate adaptation leads 
to the development of hyperglycemia and eventually diabetes mellitus (Chiasson et al., 
2003). An antidiabetic agent could exert a beneficial effect in the diabetic situation by 
enhancing insulin secretion and/or by improving/mimicking insulin action (Gray & Flatt, 
2007). This is the first time that it shown that HH, increase insulin secretion from 
pancreatic β-cells isolated from rats. 
 
Glucose stimulated insulin secretion in low (3mM) and high (20mM) concentrations 
(Figure 4.14). Furthermore, insulin secretion was significantly higher when the glucose 
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concentration was increased from 3mM to 20 mM (1.10 ± 0.13 μUI/ml protein and 1.5 ± 
0.17 mIU/mg protein respectively P ≤ 0.01). The result of this study is in agreement with 
that of  Purrello et al. (1989) who also observed increased insulin secretion in the presence 
of low (5.5mM) and high (16.7mM) glucose concentrations. Henquin (2004) demonstrate 
of that the blockade of KATP channels in the plasma membrane of β-cells is a key step in the 
stimulation of insulin release by glucose and by many pharmacological components. This 
results in stimulation of the Ca
+2
 influx, and increase the cytosolic concentration of free 
Ca
+2
, which constitutes the triggering signal to induce exocytosis of insulin granules. The 
mechanism of glucose-induced desensitization in β-cells is not known. Evidence indicates 
that this phenomenon is not a consequence of impaired insulin synthesis (Purrello et al., 
1989). Farmer et al. (2012) which demonstrate that the mechanism of glucose stimulated 
the insulin secretion in a dose-dependent manner. The present study has also shown the 
beneficial use of HH to induce insulin secretion from pancreatic islet cells. In the presence 
of low HH (100 µg/ml), there was a marked increase in insulin secretion when exposed to 
high glucose compared to low glucose concentration, while, in the presence of high HH 
(500 µg/ml), there was no significant different in insulin secretion in the presence of low or 
high glucose. Interestingly, in the presence of glibenclamide (10 mg/ml), the insulin 
secretion increased after exposure to high glucose compared to low glucose.  
 
Figures 4.15 and 4.16 illustrates that at the higher HH concentration (500 µg/ml), insulin 
secretion is higher than at the low HH concentration  (100 µg/ml) at both low (3mM) and 
high (20mM) glucose levels. On closer inspection it appears that at 500 µg/ml HH, insulin 
secretion is the same at both 3mM glucose ( 2.34 ± 0.24 mIU/mg protein) and 20mM 
glucose (2.35 ± 0.17 mIU/µg protein) (Figure 4.15). Furthermore, these values also 
correspond with the maximum insulin secretion achieved with 10 mg/ml glibenclamide in 
the study (Figure 4.15), It thus appears as if this is the maximum amount of insulin that can 
be secreted over the hour measured. We do not know whether the rate of insulin secretion 
remained constant over the 60 minutes. It is possible that the β-cells became either 
desensitized or exhausted. There are two clear concepts for glucose-induced 
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desensitization, the first is a consequence of functional changes in the β-cell that impair 
glucose-recognition. The second, results from increased secretory activity  in the β-cell that 
leads to a depletion of releasable insulin (Rustenbeck, 2002). Increase insulin secretion 
from β-cells occurs by two mechanisms. The first, under high-glucose conditions, 
proceeded by a classical secretory pathway involving KATP channel closure, membrane 
depolarization, calcium channel gating, and calcium mobilization. The second mechanism, 
under low-glucose conditions, may occurs independently of glucose metabolism (Ammälä 
et al., 1993; Haidar et al., 2004). 
 
5.4 Conclusions 
 
Our objectives were: 
 To determine whether HH can control blood glucose levels in diabetes animal 
models. 
 To determine whether HH can increase pancreatic insulin secretion 
 
The results of this experimental study indicate that a dose 800 mg/kg of HHS produces 
maximal hypoglycaemic effects in fasted normal and diabetic rats in our acute experiment. 
Also, HH in chronic doses has an antidiabetic activity as it lowers serum glucose levels in 
diabetic rats and significantly increases glucose tolerance. It also increases body weight of 
diabetic rats. We also found that HH treatment improved insulin secretion in pancreatic 
islet cells. Further studies are necessary to investigate the exact mechanism by which HH 
stimulates insulin secretion of pancreatic islet cells. 
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